N-sulfonylcarboximidamide apoptosis promoters

ABSTRACT

Compounds having the formula 
     
       
         
         
             
             
         
       
     
     are apoptosis promoters. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

This application claims benefit to provisional application No.60/574,500, filed May 26, 2004.

TECHNICAL FIELD

The present invention relates to substituted N-sulfonylcarboximidamideswhich are useful for promoting apoptosis, methods of making thecompounds, compositions containing the compounds, and methods oftreatment using the compounds.

BACKGROUND OF THE INVENTION

Apoptosis is a mode of cell death in which the cell commits suicideeither to ensure proper development of the organism or to destroy cellsthat represent a threat to the organism's integrity. Morphologically,apoptosis is characterized by blebbing of the plasma membrane, shrinkingof the cytoplasm and nucleus, and fragmenting into particles which areengulfed by phagocytic cells. Although apoptosis plays a critical rolein normal development, its impairment is thought to be a significantfactor in the etiology of such diseases as cancer, autoimmune disorders,inflammatory diseases, and viral infections. Conversely, increasedapoptosis has been linked to AIDS and neurodegenerative diseases such asParkinson's disease, stroke, and Alzheimer's disease.

Bcl-X_(L) is a protein which, in healthy cells, is expressed in theouter membranes of the mitochondria, the endoplasmic reticulum, and thenuclear envelope. Its function is to bind to specific protein/proteasecomplexes and prevent cell apoptosis. Upon internal damage to the cellthe protein/protease complexes are released, and cause the process ofapoptosis to begin. An over-expression of Bcl-X_(L), often present incancerous and other diseased cells, results in the blocking of apoptoticsignals and allows the cells to proliferate. It is believed that byblocking Bcl-X_(L), apoptosis can be induced in diseased cells, and canprovide an effective therapy for cancer and other diseases caused by theimpairment of the apoptotic process. Based on these findings and theabsence of small molecule Bcl-X_(L) inhibitors from current cancertherapies, there is a continuing need for compounds which can triggerapoptosis through the inhibition of the Bcl family of proteins.

SUMMARY OF THE INVENTION

In its principle embodiment the present invention provides a compound offormula (I)

or a therapeutically acceptable salt thereof, wherein

A is a five-, six-, or seven-membered aromatic or non-aromatic ringwherein from zero to three carbon atoms are replaced by a heteroatomselected from the group consisting of nitrogen, oxygen, and sulfur;

R¹ is selected from the group consisting of alkyl, cyano, halo,haloalkyl, nitro, and

—NR⁵R⁶;

R², and R³ are independently selected from the group consisting ofhydrogen, alkenyl, alkoxy, alkyl, alkylcarbonyloxy, alkylsulfanyl,alkynyl, aryl, arylalkoxy, aryloxy, aryloxyalkoxy, arylsulfanyl,arylsulfanylalkoxy, cycloalkylalkoxy, cycloalkyloxy, halo, haloalkoxy,haloalkyl, heterocyclyl, heterocyclyloxy, hydroxy, nitro, and —NR⁵R⁶;

R⁴ is selected from the group consisting of aryl, arylalkenyl,arylalkoxy, cycloalkenyl, cycloalkyl, heterocyclyl, andheterocyclylalkoxy;

R⁵ and R⁶ are independently selected from the group consisting ofhydrogen, alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl,alkylsulfanylalkyl, alkylsulfonylalkyl, aryl, arylalkyl,arylalkylsulfanylalkyl, aryloxyalkyl, arylsulfanylalkyl,arylsulfinylalkyl, arylsulfonylalkyl, carboxyalkyl, cycloalkenyl,cycloalkenylalkyl, cycloalkyl, (cycloalkyl)alkyl, cycloalkylcarbonyl,heterocyclyl, heterocyclylalkyl, heterocyclylsulfanylalkyl,hydroxyalkyl, and a nitrogen protecting group; or

R⁵ and R⁶, together with the nitrogen atom to which they are attached,form a ring selected from the group consisting of imidazolyl,morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, pyrrolyl,thiomorpholinyl, and thiomorpholinyl dioxide; and

R¹⁵ is selected from the group consisting of hydrogen, alkoxy, alkyl,and halo.

In a preferred embodiment the present invention provides a compound offormula (I) where R³ and R¹⁵ are hydrogen.

In another preferred embodiment the present invention provides acompound of formula (I) where R³ and R¹⁵ are hydrogen and R² is —NR⁵R⁶.

In another preferred embodiment the present invention provides acompound of formula (I) where R³ and R¹⁵ are hydrogen, R² is —NR⁵R⁶, oneof R⁵ and R⁶ is hydrogen and the other is arylsulfanylalkyl.

In another preferred embodiment the present invention provides acompound of formula (I) where R³ and R¹⁵ are hydrogen, R² is —NR⁵R⁶, oneof R⁵ and R⁶ is hydrogen and the other is arylsulfanylalkyl, and A ispiperazinyl.

Examples of compounds supporting this embodiment are

-   4-(4-benzyl-4-methoxycyclohexyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-1-piperazinecarboximidamide;-   N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-phenyl-1-piperazinecarboximidamide;-   N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-methoxy-4-(2-methylbenzyl)cyclohexyl)-1-piperazinecarboximidamide;-   4-(4-(2-chlorobenzyl)-4-methoxycyclohexyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-1-piperazinecarboximidamide;-   N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-fluorobenzyl)-4-methoxycyclohexyl)-1-piperazinecarboximidamide;    and-   4-(4-(2-bromobenzyl)-4-methoxycyclohexyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-1-piperazinecarboximidamide.

In another preferred embodiment the present invention provides acompound of formula (I) where R³ and R¹⁵ are hydrogen, R² is —NR⁵R⁶, oneof R⁵ and R⁶ is hydrogen and the other is arylsulfanylalkyl, and A isphenyl.

In another preferred embodiment the present invention provides acompound of formula (I) where R³ and R¹⁵ are hydrogen, R² is —NR⁵R⁶, oneof R⁵ and R⁶ is hydrogen and the other is arylsulfanylalkyl, A isphenyl, and R⁴ is piperidinyl.

EXAMPLEs of compounds supporting this embodiment are

-   N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-fluorobenzyl)-4-methoxy-1-piperidinyl)benzenecarboximidamide;-   N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4,4-dimethyl-1-piperidinyl)benzenecarboximidamide;-   N-((4-(((1R)-5-(dimethylamino)-1-((phenylsulfanyl)methyl)pentyl)amino)-3-nitrophenyl)sulfonyl)-4-(4,4-dimethyl-1-piperidinyl)benzenecarboximidamide;-   4-(4,4-dimethyl-1-piperidinyl)-N-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide;-   4-(4-benzyl-4-methoxy-1-piperidinyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;-   4-(4-(cyclohexylmethyl)-4-methoxy-1-piperidinyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;-   4-(4-(2,4-difluorobenzyl)-4-methoxy-1-piperidinyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;-   N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-methoxy-4-(2-methylbenzyl)-1-piperidinyl)benzenecarboximidamide;-   N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(4-fluorobenzylidene)-1-piperidinyl)benzenecarboximidamide;-   N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-(trifluoromethyl)benzylidene)-1-piperidinyl)benzenecarboximidamide;-   N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(3-thienylmethylene)-1-piperidinyl)benzenecarboximidamide;-   4-(4-methoxy-4-(2-methylbenzyl)-1-piperidinyl)-N-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide;-   N-((4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-methoxy-4-(2-methylbenzyl)-1-piperidinyl)benzenecarboximidamide;-   4-(4-methoxy-4-(2-methylbenzyl)-1-piperidinyl)-N-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;-   4-(4-(1,1′-biphenyl-2-ylmethyl)-4-methoxy-1-piperidinyl)-N-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide;-   4-(4-(1,1′-biphenyl-2-ylmethyl)-4-methoxy-1-piperidinyl)-N-((4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;-   4-(4-(1,1′-biphenyl-2-ylmethyl)-4-methoxy-1-piperidinyl)-N-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;-   4-(4-(1,1′-biphenyl-2-ylmethylene)-1-piperidinyl)-N′-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide;-   4-(4-(1,1′-biphenyl-2-ylmethylene)-1-piperidinyl)-N′-((4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;-   4-(4-(1,1-biphenyl-2-ylmethylene)-1-piperidinyl)-N′-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;-   N′-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)-4-(4-(2-(trifluoromethyl)benzylidene)-1-piperidinyl)benzenecarboximidamide;-   N′-((4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-(trifluoromethyl)benzylidene)-1-piperidinyl)benzenecarboximidamide;    and-   N′-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-(trifluoromethyl)benzylidene)-1-piperidinyl)benzenecarboximidamide.

In another preferred embodiment the present invention provides acompound of formula (I) where R³ and R¹⁵ are hydrogen, R² is —NR⁵R⁶, oneof R⁵ and R⁶ is hydrogen and the other is arylsulfanylalkyl, A isphenyl, and R⁴ is piperazinyl.

EXAMPLEs of compounds supporting this embodiment are

-   N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(3,3-diphenyl-2-propenyl)-1-piperazinyl)benzenecarboximidamide;-   4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)-1-piperazinyl)-N-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide;-   4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)-1-piperazinyl)-N-((4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;-   4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)-1-piperazinyl)-N-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;-   4-(4-(3,3-diphenyl-2-propenyl)-1-piperazinyl)-N′-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide;-   N′-((4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(3,3-diphenyl-2-propenyl)-1-piperazinyl)benzenecarboximidamide;    and-   4-(4-(3,3-diphenyl-2-propenyl)-1-piperazinyl)-N′-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide.

In another embodiment, the present invention discloses a pharmaceuticalcomposition comprising a compound of formula (I), or a therapeuticallyacceptable salt thereof, in combination with a therapeuticallyacceptable carrier.

In another embodiment, the present invention discloses a method ofpromoting apoptosis in a mammal in recognized need of such treatmentcomprising administering to the mammal a therapeutically acceptableamount of a compound of formula (I), or a therapeutically acceptablesalt thereof.

DETAILED DESCRIPTION OF THE INVENTION

Compounds of the present invention comprise substitutedN-sulfonylcarboximidamides which are useful for the treatment ofapoptosis-mediated diseases.

All patents, patent applications, and literature references cited in thespecification are herein incorporated by reference in their entirety. Inthe case of inconsistencies, the present disclosure, includingdefinitions, will prevail.

As used in the present specification the following terms have themeanings indicated:

The term “alkenyl,” as used herein, refers to a straight or branchedchain group of one to twelve carbon atoms derived from a straight orbranched chain hydrocarbon containing at least one carbon-carbon doublebond.

The term “alkenylene,” as used herein, refers to a group of two to sixatoms derived from an unsaturated straight or branched chainhydrocarbon.

The term “alkoxy,” as used herein, refers to an alkyl group attached tothe parent molecular moiety through an oxygen atom.

The term “alkoxyalkoxy,” as used herein, refers to an alkoxyalkyl groupattached to the parent molecular moiety through an oxygen atom.

The term “alkoxyalkoxyalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three alkoxyalkoxy groups.

The term “alkoxyalkoxycarbonyl,” as used herein, refers to analkoxyalkoxy group attached to the parent molecular moiety through acarbonyl group.

The term “alkoxyalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three alkoxy groups.

The term “alkoxyalkylcarbonyl,” as used herein, refers to an alkoxyalkylgroup attached to the parent molecular moiety through a carbonyl group.

The term “alkoxycarbonyl,” as used herein, refers to an alkoxy groupattached to the parent molecular moiety through a carbonyl group.

The term “alkoxycarbonylalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three alkoxycarbonyl groups.

The term “alkyl,” as used herein, refers to a group of one to twelvecarbon atoms derived from a straight or branched chain saturatedhydrocarbon.

The term “alkylcarbonyl,” as used herein, refers to an alkyl groupattached to the parent molecular moiety through a carbonyl group. Thealkylcarbonyl groups of this invention can be optionally substitutedwith one or two groups independently selected from the group consistingof hydroxy and —NR⁵R⁶, wherein R⁵ and R⁶ are as previously defined.

The term “alkylcarbonylalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three alkylcarbonyl groups.

The term “alkylcarbonyloxy,” as used herein, refers to an alkylcarbonylgroup attached to the parent molecular moiety through an oxygen atom.

The term “alkylene,” as used herein, refers to a group of two to sixatoms derived from a saturated straight or branched chain hydrocarbon.

The term “alkylidene,” as used herein, refers to an alkenyl group inwhich one carbon atom of the carbon-carbon double bond belongs to themoiety to which the alkenyl group is attached.

The term “alkylsulfanyl,” as used herein, refers to an alkyl groupattached to the parent molecular moiety through a sulfur atom.

The term “alkylsulfanylalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three alkylsulfanyl groups.

The term “alkylsulfonyl,” as used herein, refers to an alkyl groupattached to the parent molecular moiety through a sulfonyl group.

The term “alkylsulfonylalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three alkylsulfonyl groups.

The term “alkynyl,” as used herein, refers to a straight or branchedchain group of one to twelve carbon atoms containing at least onecarbon-carbon triple bond.

The term “aryl,” as used herein, refers to a phenyl group, or a bicyclicor tricyclic fused ring system wherein one or more of the rings is aphenyl group. Bicyclic fused ring systems consist of a phenyl groupfused to a monocyclic cycloalkenyl group, a monocyclic cycloalkyl group,or another phenyl group. Tricyclic fused ring systems consist of abicyclic fused ring system fused to a monocyclic cycloalkenyl group, amonocyclic cycloalkyl group, or another phenyl group. The aryl groups ofthe present invention can be attached to the parent molecular moietythrough any substitutable carbon atom in the group. RepresentativeEXAMPLEs of aryl groups include, but are not limited to, anthracenyl,azulenyl, fluorenyl, indanyl, indenyl, naphthyl, phenyl, andtetrahydronaphthyl. Preferred aryl groups of the present inventioninclude phenyl. The aryl groups of the present invention can beoptionally substituted with one, two, three, four, or five substituentsindependently selected from the group consisting of alkenyl, alkoxy,alkoxyalkyl, alkoxyalkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl,alkyl, alkylcarbonyl, alkylcarbonyloxy, alkynyl, a second aryl group,arylalkoxy, aryloxy, arylsulfanyl, cyano, halo, haloalkoxy, haloalkyl,heterocyclyl, heterocyclylalkyl, heterocyclylcarbonylalkenyl,heterocyclylcarbonylalkyl, hydroxy, hydroxyalkyl, nitro, —NR^(a)R^(b),(NR^(a)R^(b))alkyl, (NR^(a)R^(b))carbonyl, (NR^(a)R^(b))carbonylalkyl,(NR^(a)R^(b))sulfonyl, oxo, and —C(NH)NH₂, wherein the second arylgroup; the aryl part of the arylalkoxy, the aryloxy, and thearylsulfanyl; the heterocyclyl; and the heterocyclyl part of theheterocyclylalkyl, the heterocyclylcarbonylalkenyl, and theheterocyclylcarbonylalkyl can be further optionally substituted withone, two, or three substituents independently selected from the groupconsisting of alkoxyalkylcarbonyl, alkoxycarbonyl, alkyl, alkylsulfonyl,cyano, halo, haloalkoxy, haloalkyl, hydroxy, nitro,(NR^(a)R^(b))carbonyl, (NR^(a)R^(b))sulfonyl, oxo, and —C(NH)NH₂. Inaddition, the heterocyclyl and the heterocyclyl part of theheterocyclylalkyl, the heterocyclylcarbonylalkenyl, and theheterocyclylcarbonylalkyl can be further optionally substituted with anadditional aryl group, wherein the additional aryl group can beoptionally substituted with one, two, or three substituentsindependently selected from the group consisting of alkoxy, alkyl,cyano, halo, hydroxy, and nitro.

The term “arylalkenyl,” as used herein, refers to an alkenyl groupsubstituted by one, two, or three aryl groups.

The term “arylalkoxy,” as used herein, refers to an arylalkyl groupattached to the parent molecular moiety through an oxygen atom.

The term “arylalkoxyalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three arylalkoxy groups.

The term “arylalkoxyalkylcarbonyl,” as used herein, refers to anarylalkoxyalkyl group attached to the parent molecular moiety through acarbonyl group.

The term “arylalkoxycarbonyl,” as used herein, refers to an arylalkoxygroup attached to the parent molecular moiety through a carbonyl group.

The term “arylalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three aryl groups. The alkyl part of thearylalkyl can be optionally substituted with one or two —NR^(a)R^(b)groups.

The term “arylalkylcarbonyl,” as used herein, refers to an arylalkylgroup attached to the parent molecular moiety through a carbonyl group.

The term “arylalkylidene,” as used herein, refers to an aryl groupattached to the parent molecular moiety through an alkylidene group.

The term “arylalkylsulfanyl,” as used herein, refers to an arylalkylgroup attached to the parent molecular moiety through a sulfur atom.

The term “arylalkylsulfanylalkyl,” as used herein, refers to an alkylgroup substituted with one, two, or three arylalkylsulfanyl groups.

The term “arylalkylsulfonyl,” as used herein, refers to an arylalkylgroup attached to the parent molecular moiety through a sulfonyl group.

The term “arylcarbonyl,” as used herein, refers to an aryl groupattached to the parent molecular moiety through a carbonyl group.

The term “aryloxy,” as used herein, refers to an aryl group attached tothe parent molecular moiety through an oxygen atom.

The term “aryloxyalkoxy,” as used herein, refers to an aryloxy groupattached to the parent molecular moiety through an alkoxy group.

The term “aryloxyalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three aryloxy groups.

The term “aryloxyalkylcarbonyl,” as used herein, refers to anaryloxyalkyl group attached to the parent molecular moiety through acarbonyl group.

The term “arylsulfanyl,” as used herein, refers to an aryl groupattached to the parent molecular moiety through a sulfur atom.

The term “arylsulfanylalkoxy,” as used herein, refers to an arylsulfanylgroup attached to the parent molecular moiety through an alkoxy group.The alkoxy part of the arylsulfanylalkoxy can be optionally substitutedwith one or two —NR^(a)R^(b) groups.

The term “arylsulfanylalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three arylsulfanyl group. The alkyl partof the arylsulfanylalkyl can be further optionally substituted with oneor two substituents independently selected from the group consisting ofalkoxy, alkoxycarbonyl, arylalkoxy, azido, carboxy, cycloalkyl, halo,heterocyclyl, heterocyclylalkoxy, heterocyclylcarbonyl, hydroxy,—NR^(a)R^(b), (NR^(a)R^(b))alkoxy, and (NR^(a)R^(b))carbonyl.

The term “arylsulfinyl,” as used herein, refers to an aryl groupattached to the parent molecular moiety through a sulfinyl group.

The term “arylsulfinylalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three arylsulfinyl groups. The alkyl partof the arylsulfinylalkyl can be further optionally substituted with oneor two —NR^(a)R^(b) groups.

The term “arylsulfonyl,” as used herein, refers to an aryl groupattached to the parent molecular moiety through a sulfonyl group.

The term “arylsulfonylalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three arylsulfonyl groups. The alkyl partof the arylsulfonylalkyl can be further optionally substituted with oneor two —NR^(a)R^(b) groups.

The term “azido,” as used herein, refers to —N₃.

The term “carbonyl,” as used herein, refers to —C(O)—.

The term “carboxy,” as used herein, refers to —CO₂H.

The term “carboxyalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three carboxy groups.

The term “cyano,” as used herein, refers to —CN.

The term “cyanoalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three cyano groups.

The term “cycloalkenyl,” as used herein, refers to a non-aromatic,partially unsaturated monocyclic, bicyclic, or tricyclic ring systemhaving three to fourteen carbon atoms and zero heteroatoms.Representative EXAMPLEs of cycloalkenyl groups include, but are notlimited to, cyclohexenyl, octahydronaphthalenyl, and norbornylenyl. Thecycloalkenyl groups of this invention can be optionally substituted withone, two, three, four, or five substituents independently selected fromthe group consisting of alkoxy, alkoxycarbonyl, alkyl, arylalkoxy,aryloxy, arylsulfanyl, halo, haloalkoxy, haloalkyl, hydroxy, and(NR^(a)R^(b))alkyl, wherein the aryl part of the arylalkoxy, thearyloxy, the arylsulfanyl, and the arylsulfanylalkyl can be furtheroptionally substituted with one, two, or three substituentsindependently selected from the group consisting of alkoxy, alkyl, halo,haloalkoxy, haloalkyl, and hydroxy.

The term “cycloalkenylalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three cycloalkenyl groups.

The term “cycloalkyl,” as used herein, refers to a saturated monocyclic,bicyclic, or tricyclic hydrocarbon ring system having three to fourteencarbon atoms and zero heteroatoms. Representative EXAMPLEs of cycloalkylgroups include, but are not limited to, cyclopropyl, cyclopentyl,bicyclo(3.1.1)heptyl, and adamantyl. The cycloalkyl groups of thisinvention can be optionally substituted with one, two, three, four, orfive substituents independently selected from the group consisting ofalkoxy, alkoxycarbonyl, alkyl, alkylidene, aryl, arylalkenyl,arylalkoxy, arylalkyl, arylalkylidene, aryloxy, arylsulfanyl,arylsulfanylalkyl, a second cycloalkyl group, (cycloalkyl)alkyl,cycloalkylalkylidene, halo, haloalkoxy, haloalkyl, heterocyclyl,heterocyclylalkoxy, heterocyclylalkyl, heterocyclylalkylidene, hydroxy,—NR^(a)R^(b), (NR^(a)R^(b))alkoxy, (NR^(a)R^(b))alkyl, spirocyclyl, andspiroheterocyclyl; wherein the aryl; the aryl part of the arylalkenyl,the arylalkoxy, the arylalkyl, the arylalkylidene, the aryloxy, thearylsulfanyl, and the arylsulfanylalkyl; the second cycloalkyl group,the cycloalkyl part of the (cycloalkyl)alkyl and thecycloalkylalkylidene; the heterocyclyl; and the heterocyclyl part of theheterocyclylalkoxy, the heterocyclylalkyl, and theheterocyclylalkylidene can be further optionally substituted with one,two, or three substituents independently selected from the groupconsisting of alkoxy, alkyl, unsubstituted aryl, cyano, halo,haloalkoxy, haloalkyl, and hydroxy.

The term “cycloalkylalkoxy,” as used herein, refers to a cycloalkylgroup attached to the parent molecular moiety through an alkoxy group.

The term “(cycloalkyl)alkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three cycloalkyl groups.

The term “cycloalkylalkylidene,” as used herein, refers to a cycloalkylgroup attached to the parent molecular moiety through an alkylidenegroup.

The term “cycloalkylcarbonyl,” as used herein, refers to a cycloalkylgroup attached to the parent molecular moiety through a carbonyl group.

The term “cycloalkyloxy,” as used herein, refers to a cycloalkyl groupattached to the parent molecular moiety through an oxygen atom.

The term “dialkylamino,” as used herein, refers to —N(R¹⁴)₂, wherein R¹⁴is alkyl.

The term “dialkylaminoalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three dialkylamino groups.

The term “dialkylaminocarbonyl,” as used herein, refers to andialkylamino group attached to the parent molecular moiety through acarbonyl group.

The term “dialkylaminocarbonylalkyl,” as used herein, refers to an alkylgroup substituted with one, two, or three dialkylaminocarbonyl groups.

The term “formyl,” as used herein, refers to —CHO.

The term “formylalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three formyl groups.

The term “halo,” as used herein, refers to F, Cl, Br, or I.

The term “haloalkoxy,” as used herein, refers to a haloalkyl groupattached to the parent molecular moiety through an oxygen atom.

The term “haloalkyl,” as used herein, refers to an alkyl groupsubstituted by one, two, three, or four halogen atoms.

The term “haloalkylcarbonyl,” as used herein, refers to a haloalkylgroup attached to the parent molecular moiety through a carbonyl group.

The term “heteroalkenylene,” as used herein, refers to an unsaturatedgroup of two to six atoms containing one or two heteroatomsindependently selected from the group consisting of nitrogen, oxygen,and sulfur, wherein the remaining atoms are carbon. The heteroalkylenegroups of the present invention can be attached to the parent molecularmoiety through the carbon atoms or the heteroatoms in the chain.

The term “heteroalkylene,” as used herein, refers to a saturated groupof two to six atoms containing one or two heteroatoms independentlyselected from the group consisting of nitrogen, oxygen, and sulfur,wherein the remaining atoms are carbon. The heteroalkylene groups of thepresent invention can be attached to the parent molecular moiety throughthe carbon atoms or the heteroatoms in the chain.

The term “heterocyclyl,” as used herein, refers to a five-, six-, orseven-membered ring containing one, two, or three heteroatomsindependently selected from the group consisting of nitrogen, oxygen,and sulfur. The five-membered ring has zero to two double bonds and thesix- and seven-membered rings have zero to three double bonds. The term“heterocyclyl” also includes bicyclic groups in which the heterocyclylring is fused to a phenyl group, a monocyclic cycloalkenyl group, amonocyclic cycloalkyl group, or another monocyclic heterocyclyl group;and tricyclic groups in which a bicyclic system is fused to a phenylgroup, a monocyclic cycloalkenyl group, a monocyclic cycloalkyl group,or another monocyclic heterocyclyl group. The heterocyclyl groups of thepresent invention can be attached to the parent molecular moiety througha carbon atom or a nitrogen atom in the group. EXAMPLEs of heterocyclylgroups include, but are not limited to, benzothienyl, furyl, imidazolyl,indolinyl, indolyl, isothiazolyl, isoxazolyl, morpholinyl, oxazolyl,piperazinyl, piperidinyl, pyrazolyl, pyridinyl, pyrrolidinyl,pyrrolopyridinyl, pyrrolyl, thiazolyl, thienyl, and thiomorpholinyl. Theheterocyclyl groups of the present invention can be optionallysubstituted with one, two, three, four, or five substituentsindependently selected from the group consisting of alkenyl, alkoxy,alkoxyalkoxycarbonyl, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl,alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy,alkylsulfanylalkyl, alkynyl, aryl, arylalkenyl, arylalkoxyalkyl,arylalkoxyalkylcarbonyl, arylalkoxycarbonyl, arylalkyl,arylalkylcarbonyl, arylalkylidene, arylalkylsulfonyl, arylcarbonyl,aryloxy, aryloxyalkylcarbonyl, arylsulfanyl, arylsulfanylalkyl,arylsulfonyl, carboxy, cyano, cyanoalkyl, cycloalkyl, (cycloalkyl)alkyl,cycloalkylcarbonyl, formyl, formylalkyl, halo, haloalkoxy, haloalkyl, asecond heterocyclyl group, heterocyclylalkenyl, heterocyclylalkyl,heterocyclylalkylcarbonyl, heterocyclylalkylidene, heterocycylcarbonyl,heterocyclylcarbonylalkyl, hydroxy, hydroxyalkyl, nitro, —NR^(a)R^(b),(NR^(a)R^(b))alkyl, (NR^(a)R^(b))alkylcarbonyl, (NR^(a)R^(b))carbonyl,(NR^(a)R^(b))carbonylalkyl, (NR^(a)R^(b))sulfonyl, oxo, spirocyclyl,spiroheterocyclyl, and —C(NH)NH₂; wherein the aryl; the aryl part of thearylalkenyl, the arylalkoxyalkyl, the arylalkoxyalkylcarbonyl, thearylalkoxycarbonyl, the arylalkyl, the arylalkylcarbonyl, thearylalkylidene, the arylalkylsulfonyl, the arylcarbonyl, the aryloxy,the aryloxyalkylcarbonyl, the arylsulfanyl, the arylsulfanylalkyl, andthe arylsulfonyl; the heterocyclyl; and the heterocycyl part of theheterocyclylalkenyl, the heterocyclylalkyl, theheterocyclylalkylcarbonyl, the heterocyclylalkylidene, theheterocyclylcarbonyl, and the heterocyclylcarbonylalkyl can be furtheroptionally substituted with one, two, three, four, or five substituentsindependently selected from the group consisting of alkoxy,alkoxyalkoxycarbonyl, alkoxycarbonyl, alkyl, alkylcarbonyl, anadditional aryl group, cyano, halo, haloalkoxy, haloalkyl, hydroxy,hydroxyalkyl, and nitro, wherein the additional aryl group can befurther optionally substituted with one, two, three, four, or fivesubstituents independently selected from the group consisting of alkoxy,alkyl, cyano, halo, haloalkoxy, haloalkyl, and nitro. In addition, thealkenyl part of the heterocyclylalkenyl can be further optionallysubstituted with one or two unsubstituted aryl groups.

The term “heterocyclylalkenyl,” as used herein, refers to an alkenylgroup substituted by one, two, or three heterocyclyl groups. The alkenylpart of the heterocyclylalkenyl can be optionally substituted with oneor two aryl groups.

The term “heterocyclylalkoxy,” as used herein, refers to a heterocyclylgroup attached to the parent molecular moiety through an alkoxy group.

The term “heterocyclylalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three heterocyclyl groups.

The term “heterocyclylalkylcarbonyl,” as used herein, refers to aheterocyclylalkyl group attached to the parent molecular moiety througha carbonyl group.

The term “heterocyclylalkylidene,” as used herein, refers to aheterocyclyl group attached to the parent molecular moiety through analkylidene group.

The term “heterocyclylcarbonyl,” as used herein, refers to aheterocyclyl group attached to the parent molecular moiety through acarbonyl group.

The term “heterocyclylcarbonylalkenyl,” as used herein, refers to analkenyl group substituted with one, two, or three heterocyclylcarbonylgroups.

The term “heterocyclylcarbonylalkyl,” as used herein, refers to an alkylgroup substituted with one, two, or three heterocyclylcarbonyl groups.

The term “heterocyclyloxy,” as used herein, refers to a heterocyclylgroup attached to the parent molecular moiety through an oxygen atom.

The term “heterocyclylsulfanyl,” as used herein, refers to aheterocyclyl group attached to the parent molecular moiety through asulfur atom.

The term “heterocyclylsulfanylalkyl,” as used herein, refers to an alkylgroup substituted with one, two, or three heterocyclylsulfanyl groups.

The term “hydroxy,” as used herein, refers to —OH.

The term “hydroxyalkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three hydroxy groups.

The term “nitro,” as used herein, refers to —NO₂.

The term “nitrogen protecting group,” as used herein, refers to groupsintended to protect an amino group against undesirable reactions duringsynthetic procedures. Common N-protecting groups comprise acyl groupssuch as acetyl, benzoyl, 2-bromoacetyl, 4-bromobenzoyl,tert-butylacetyl, carboxaldehyde, 2-chloroacetyl, 4-chlorobenzoyl,a-chlorobutyryl, 4-nitrobenzoyl, o-nitrophenoxyacetyl, phthalyl,pivaloyl, propionyl, trichloroacetyl, and trifluoroacetyl; sulfonylgroups such as benzenesulfonyl, and p-toluenesulfonyl; carbamate forminggroups such as benzyloxycarbonyl, benzyloxycarbonyl (Cbz),tert-butyloxycarbonyl (Boc), p-chlorobenzyloxycarbonyl,p-methoxybenzyloxycarbonyl, and the like.

The term “—NR^(a)R^(e),” as used herein, refers to two groups, R^(a) andR^(b), which are attached to the parent molecular moiety through anitrogen atom. R^(a) and R^(b) are independently selected from the groupconsisting of hydrogen, alkenyl, alkoxyalkyl, alkoxyalkoxyalkyl,alkoxycarbonyl, alkyl, alkylcarbonyl, aryl, arylalkoxycarbonyl,arylalkyl, arylalkylcarbonyl, arylcarbonyl, arylsulfonyl, cycloalkyl,(cycloalkyl)alkyl, cycloalkylcarbonyl, dialkylaminoalkyl,dialkylaminocarbonylalkyl, haloalkyl, haloalkylcarbonyl, heterocyclyl,heterocyclylalkyl, heterocyclylcarbonyl, hydroxyalkyl, a nitrogenprotecting group, —C(NH)NH₂, and —C(O)(CH₂)_(n)NR⁵R⁶, wherein n is 0, 1,2, or 3; and R⁵ and R⁶ are as previously defined; wherein the aryl; thearyl part of the arylalkoxycarbonyl, the arylalkyl, thearylalkylcarbonyl, the arylcarbonyl, and the arylsulfonyl; thecycloalkyl; the cycloalkyl part of the (cycloalkyl)alkyl and thecycloalkylcarbonyl; the heterocyclyl; and the heterocycyl part of theheterocyclylalkyl and the heterocyclylcarbonyl can be optionallysubstituted with one, two, three, four, or five substituentsindependently selected from the group consisting of alkoxy, alkyl,alkylcarbonyl, cyano, halo, haloalkoxy, haloalkyl, hydroxy, and nitro.

The term “(NR^(a)R^(b))alkoxy,” as used herein, refers to an(NR^(a)R^(b))alkyl group attached to the parent molecular moiety throughan oxygen atom.

The term “(NR^(a)R^(b))alkyl,” as used herein, refers to an alkyl groupsubstituted with one, two, or three —NR^(a)R^(b) groups.

The term “(NR^(a)R^(b))alkylcarbonyl,” as used herein, refers to an—NR^(a)R^(b) group attached to the parent molecular moiety through analkylcarbonyl group.

The term “(NR^(a)R^(b))carbonyl,” as used herein, refers to an—NR^(a)R^(b) group attached to the parent molecular moiety through acarbonyl group.

The term “(NR^(a)R^(b))carbonylalkyl,” as used herein, refers to analkyl group substituted with one, two, or three (NR^(a)R^(b))carbonylgroups.

The term “(NR^(a)R^(b))sulfonyl,” as used herein, refers to an—NR^(a)R^(b) group attached to the parent molecular moiety through asulfonyl group.

The term “oxo,” as used herein, refers to (═O).

The term “spirocyclyl,” as used herein, refers to an alkenylene oralkylene group in which both ends of the alkenylene or alkylene groupare attached to the same carbon of the parent molecular moiety to form abicyclic group. The spirocyclyl groups of the present invention can beoptionally substituted with one substituent selected from the groupconsisting of alkyl, aryl, arylalkoxyalkyl, arylalkyl, and aryloxyalkyl.

The term “spiroheterocyclyl,” as used herein, refers to aheteroalkenylene or heteroalkylene group in which both ends of theheteroalkenylene or heteroalkylene group are attached to the same carbonof the parent molecular moiety to form a bicyclic group. Thespiroheterocyclyl groups of the present invention can be optionallysubstituted with one substituent selected from the group consisting ofalkyl, aryl, arylalkoxyalkyl, arylalkyl, and aryloxyalkyl.

The term “sulfinyl,” as used herein, refers to —S(O)—.

The term “sulfonyl,” as used herein, refers to —SO₂—.

The term “therapeutically acceptable salt,” as use herein, refers tothose salts which are, within the scope of sound medical judgment,suitable for use in contact with the tissues of humans and lower animalswithout undue toxicity, irritation, allergic response and the like andare commensurate with a reasonable benefit/risk ratio. The salts can beprepared in situ during the final isolation and purification of thecompounds of the present invention or separately by reacting a free basegroup with a suitable organic acid. Representative acid addition saltsinclude acetate, adipate, alginate, ascorbate, aspartate,benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate,camphorsulfonate, citrate, cyclopentanepropionate, digluconate,dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate,glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide,hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate,lactate, laurate, lauryl sulfate, malate, maleate, malonate,methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate,oxalate, palmitate, palmoate, pectinate, persulfate, 3-phenylpropionate,phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate,tartrate, thiocyanate, toluenesulfonate, trifluoroacetate, undecanoate,valerate salts, and the like. Representative alkali or alkaline earthmetal salts include calcium, lithium, magnesium, potassium, sodium, andthe like, as well as non-toxic ammonium, quaternary ammonium, and aminecations, including, but not limited to, ammonium, dimethylamine,ethylamine, methylamine, tetraethylammonium, tetramethylammonium,triethylamine, trimethylamine, and the like.

Basic addition salts can be prepared during the final isolation andpurification of the compounds by reacting a carboxy group with asuitable base such as the hydroxide, carbonate, or bicarbonate of ametal cation or with ammonia or an organic primary, secondary, ortertiary amine. The cations of therapeutically acceptable salts includelithium, sodium, potassium, calcium, magnesium, and aluminum, as well asnontoxic quaternary amine cations such as ammonium, tetramethylammonium,tetraethylammonium, methylamine, dimethylamine, trimethylamine,triethylamine, diethylamine, ethylamine, tributylamine, pyridine,N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine,dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine,1-ephenamine, and N,N′-dibenzylethylenediamine. Other representativeorganic amines useful for the formation of base addition salts includeethylenediamine, ethanolamine, diethanolamine, piperidine, andpiperazine.

The present compounds can also exist as therapeutically acceptableprodrugs. The term “therapeutically acceptable prodrug,” refers to thoseprodrugs or zwitterions which are suitable for use in contact with thetissues of patients without undue toxicity, irritation, and allergicresponse, are commensurate with a reasonable benefit/risk ratio, and areeffective for their intended use. The term “prodrug,” refers tocompounds which are rapidly transformed in vivo to parent compounds offormula (I) for example, by hydrolysis in blood.

Asymmetric centers exist in the compounds of the present invention.These centers are designated by the symbols “R” or “S.” depending on theconfiguration of substituents around the chiral carbon atom. It shouldbe understood that the invention encompasses all stereochemical isomericforms, or mixtures thereof, which possess the ability to induceapoptosis. Individual stereoisomers of compounds can be preparedsynthetically from commercially available starting materials whichcontain chiral centers or by preparation of mixtures of enantiomericproducts followed by separation such as conversion to a mixture ofdiastereomers followed by separation or recrystallization,chromatographic techniques, or direct separation of enantiomers onchiral chromatographic columns. Starting compounds of particularstereochemistry are either commercially available or can be made andresolved by techniques known in the art.

According to methods of treatment, the compounds of the presentinvention can be useful for the prevention of metastases from the tumorsdescribed above either when used alone or in combination withradiotherapy and/or other chemotherapeutic treatments conventionallyadministered to patients for treating cancer. When using the compoundsof the present invention for chemotherapy, the specific therapeuticallyeffective dose level for any particular patient will depend upon factorssuch as the disorder being treated and the severity of the disorder; theactivity of the particular compound used; the specific compositionemployed; the age, body weight, general health, sex, and diet of thepatient; the time of administration; the route of administration; therate of excretion of the compound employed; the duration of treatment;and drugs used in combination with or coincidentally with the compoundused. For example, when used in the treatment of solid tumors, compoundsof the present invention can be administered with chemotherapeuticagents such as alpha inteferon, COMP (cyclophosphamide, vincristine,methotrexate, and prednisone), etoposide, mBACOD (methortrexate,bleomycin, doxorubicin, cyclophosphamide, vincristine, anddexamethasone), PRO-MACE/MOPP (prednisone, methotrexate (w/leucovinrescue), doxorubicin, cyclophosphamide, taxol,etoposide/mechlorethamine, vincristine, prednisone, and procarbazine),vincristine, vinblastine, angioinhibins, TNP-470, pentosan polysulfate,platelet factor 4, angiostatin, LM-609, SU-101, CM-101, Techgalan,thalidomide, SP-PG, and the like. For example, a tumor may be treatedconventionally with surgery, radiation or chemotherapy and a compound ofthe present invention subsequently administered to extend the dormancyof micrometastases and to stabilize and inhibit the growth of anyresidual primary tumor.

The compounds of the present invention can be administered orally,parenterally, osmotically (nasal sprays), rectally, vaginally, ortopically in unit dosage formulations containing carriers, adjuvants,diluents, vehicles, or combinations thereof. The term “parenteral”includes infusion as well as subcutaneous, intravenous, intramuscular,and intrasternal injection.

Parenterally administered aqueous or oleaginous suspensions of thecompounds of the present invention can be formulated with dispersing,wetting, or suspending agents. The injectable preparation can also be aninjectable solution or suspension in a diluent or solvent. Among theacceptable diluents or solvents employed are water, saline, Ringer'ssolution, buffers, dilute acids or bases, dilute amino acid solutions,monoglycerides, diglycerides, fatty acids such as oleic acid, and fixedoils such as monoglycerides or diglycerides.

The chemotherapeutic effect of parenterally administered compounds canbe prolonged by slowing their absorption. One way to slow the absorptionof a particular compound is administering injectable depot formscomprising suspensions of crystalline, amorphous, or otherwisewater-insoluble forms of the compound. The rate of absorption of thecompound is dependent on its rate of dissolution which is, in turn,dependent on its physical state. Another way to slow absorption of aparticular compound is administering injectable depot forms comprisingthe compound as an oleaginous solution or suspension. Yet another way toslow absorption of a particular compound is administering injectabledepot forms comprising microcapsule matrices of the compound trappedwithin liposomes, microemulsions, or biodegradable polymers such aspolylactide-polyglycolide, polyorthoesters or polyanhydrides. Dependingon the ratio of drug to polymer and the composition of the polymer, therate of drug release can be controlled.

Transdermal patches also provide controlled delivery of the compounds.The rate of absorption can be slowed by using rate controlling membranesor by trapping the compound within a polymer matrix or gel. Conversely,absorption enhancers can be used to increase absorption.

Solid dosage forms for oral administration include capsules, tablets,pills, powders, and granules. In these solid dosage forms, the activecompound can optionally comprise diluents such as sucrose, lactose,starch, talc, silicic acid, aluminum hydroxide, calcium silicates,polyamide powder, tableting lubricants, and tableting aids such asmagnesium stearate or microcrystalline cellulose. Capsules, tablets andpills can also comprise buffering agents; and tablets and pills can beprepared with enteric coatings or other release-controlling coatings.Powders and sprays can also contain excipients such as talc, silicicacid, aluminum hydroxide, calcium silicate, polyamide powder, ormixtures thereof. Sprays can additionally contain customary propellantssuch as chlorofluorohydrocarbons or substitutes thereof.

Liquid dosage forms for oral administration include emulsions,microemulsions, solutions, suspensions, syrups, and elixirs comprisinginert diluents such as water. These compositions can also compriseadjuvants such as wetting, emulsifying, suspending, sweetening,flavoring, and perfuming agents.

Topical dosage forms include ointments, pastes, creams, lotions, gels,powders, solutions, sprays, inhalants, and transdermal patches. Thecompound is mixed under sterile conditions with a carrier and any neededpreservatives or buffers. These dosage forms can also include excipientssuch as animal and vegetable fats, oils, waxes, paraffins, starch,tragacanth, cellulose derivatives, polyethylene glycols, silicones,bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.Suppositories for rectal or vaginal administration can be prepared bymixing the compounds of the present invention with a suitablenonirritating excipient such as cocoa butter or polyethylene glycol,each of which is solid at ordinary temperature but fluid in the rectumor vagina. Ophthalmic formulations comprising eye drops, eye ointments,powders, and solutions are also contemplated as being within the scopeof the present invention.

The total daily dose of the compounds of the present inventionadministered to a host in single or divided doses can be in amounts fromabout 0.1 to about 200 mg/kg body weight or preferably from about 0.25to about 100 mg/kg body weight. Single dose compositions can containthese amounts or submultiples thereof to make up the daily dose.

Determination of Biological Activity

Assays for the inhibition of Bcl-X_(L) were performed in 96-wellmicrotiter plates. Compounds of the present invention were diluted inDMSO to concentrations between 100 μM and 1 pM and introduced into eachcell of the plate. A mixture totaling 125 μL per well of assay buffer(20 mM phosphate buffer (pH 7.4), 1 mM EDTA, 0.05% PEG-8000), 50 nM ofBCL-X_(L) protein (prepared according to the procedure described inScience 1997, 275, 983-986), 5 nM fluorescein-labeled BAD peptide(purchased from Synpep, CA), and the DMSO solution of the compound ofthe present invention was shaken for 2 minutes and placed in a LJLAnalyst (LJL Bio Systems, CA). A negative control (DMSO, 5 nM BADpeptide, assay buffer) and a positive control (DMSO, 5 nM BAD peptide,50 nM BCL-X_(L), assay buffer) were used to determine the range of theassay. Polarization was measured at room temperature using a continuousFluorescein lamp (excitation 485 mM, emission 530 mM). Percentage ofinhibition was determined by (1−((mP value of well-negativecontrol)/range))×100%. IC₅₀ values were calculated using MicrosoftExcel. Compounds of the present invention have IC₅₀ values between about0.010 and about 10 μM and are therefore useful for inhibiting BCL-X_(L)and treating apoptosis-mediated diseases. Preferred compounds of thepresent invention have IC₅₀ values between about 0.010 μM and about 0.05μM.

Assays for the inhibition of Bcl-2 were performed in 96-well microtiterplates. Compounds of the instant invention were diluted in DMSO toconcentrations between 100 μM and 1 pM and introduced into each well ofthe plate. A mixture totaling 125 μL per well of assay buffer (20 mMphosphate buffer (pH 7.4), 1 mM EDTA, 0.05% PF-68), 30 nM of Bcl-2protein (prepared according to the procedure described in PNAS 2001, 98,3012-3017), 5 nM fluorescein-labeled BAX peptide (prepared in-house),and the DMSO solution of the compound of the instant invention wasshaken for 2 minutes and placed in a LJL Analyst (LJL Bio Systems, CA).A negative control (DMSO, 5 nM BAX peptide, assay buffer) and a positivecontrol (DMSO, 5 nM BAX peptide, 30 nM Bcl-2, assay buffer) were used todetermine the range of the assay. Polarization was measured at roomtemperature using a continuous Fluorescein lamp (excitation 485 mM,emission 530 mM). Percentage of inhibition was determined by (1−((mPvalue of well-negative control)/range))×100%. IC₅₀ values werecalculated using Microsoft Excel. Compounds of the present inventionhave IC₅₀ values between about 0.001 and about 10 μM and are thereforeuseful for inhibiting Bcl-2 and treating apoptosis-mediated diseases.

Based upon the structural and functional similarity of the Bclantiapoptotic proteins, it is reasonable to expect that in addition toinducing apoptosis by the inhibition of Bcl-X_(L) and Bcl-2, the currentinvention may induce apoptosis through their action on otherantiapoptotic proteins in the Bcl family of proteins, such as Bcl-w,Bcl-b, MCL-1 and/or Al/Bfl-1.

Synthetic Methods

Abbreviations which have been used in the descriptions of the scheme andthe examples that follow are: THF for tetrahydrofuran; DMSO fordimethylsulfoxide; HMPA for hexamethylphosphoramide; DMF forN,N-dimethylformamide; nBuLi for n-butyllithium; LiHMDS for lithiumhexamethyldisilazide; DME for 1,2-dimethoxyethane; PPh₃ fortriphenylphosphine; and OAc for acetate.

The compounds and processes of the present invention will be betterunderstood in connection with the following synthetic schemes whichillustrate the methods by which the compounds of the invention may beprepared. Additional methods for the formation of the compounds of thepresent invention can be found in commonly owned WO03/080586. Startingmaterials can be obtained from commercial sources or prepared bywell-established literature methods known to those of ordinary skill inthe art. It will be readily apparent to one of ordinary skill in the artthat the compounds defined above can be synthesized by substitution ofthe appropriate reactants and agents in the syntheses shown below. Thegroups R¹, R², R³, R⁴, and R¹⁵ are as defined above unless otherwisenoted below. It will be readily apparent to one skilled in the art thatthe selective protection and deprotections steps, as well as the orderof the steps themselves, can be carried out in varying order, dependingon the nature of R¹, R², R³, R⁴, R¹⁵, R^(a), R^(b), and R^(c), tosuccessfully complete the syntheses shown below.

This invention is intended to encompass compounds having formula (I)when prepared by synthetic processes or by metabolic processes.Preparation of the compounds of the invention by metabolic processesinclude those occurring in the human or animal body (in vivo) orprocesses occurring in vitro.

As shown in Scheme 1, compounds of formula (2) (which can be preparedaccording to the procedures described in Scheme 2 and examples listedbelow) can be reacted with compounds of formula (3) in which LG is anappropriate leaving group (which can be prepared by treatment of theappropriately substituted aromatic ring with chlorosulfonic acid) in thepresence of a base such as triethylamine or diisopropylethylamine toprovide compounds of formula (4) that can be reacted with a nucleophile,R²H to provide compounds of formula (I).

Scheme 2 shows the synthesis of compounds of formula (2). Compounds offormula (6) (which can be prepared according to procedures described incommonly owned U.S. patent application Ser. No. 09/957,256, filed Sep.20, 2001, or by procedures described in commonly owned U.S. patentapplication Ser. No. 10/269,739, filed Oct. 14, 2002) can be treatedwith an activating agent such as thionyl chloride, oxalyl chloride orcarbonyldiimidazole followed by aqueous ammonia to provide compounds offormula (7). Compounds of formula (7) can be treated with dehydratingagents such as oxalyl chloride or phosphorous oxychloride to providenitrites of formula (8). Alternatively, compounds of formula (5) where Xis bromine, iodine, or chlorine can be converted to compounds of formula(8) by treatment with an appropriate metallocyanide species in thepresence of Pd(0). Nitriles of formula (8) can be converted to compoundsof formula (2) by treatment with HCl in ethanol followed by ammonia, orby treatment with lithium hexamethyldisilazide followed by aqueous acid.

The present invention will now be described in connection with certainpreferred embodiments which are not intended to limit its scope. On thecontrary, the present invention covers all alternatives, modifications,and equivalents as can be included within the scope of the claims. Thus,the following examples, which include preferred embodiments, willillustrate the preferred practice of the present invention, it beingunderstood that the examples are for the purposes of illustration ofcertain preferred embodiments and are presented to provide what isbelieved to be the most useful and readily understood description of itsprocedures and conceptual aspects.

Compounds of the invention were named by ACD/ChemSketch version 5.0(developed by Advanced Chemistry Development, Inc., Toronto, ON, Canada)or were given names which appeared to be consistent with ACDnomenclature.

Example 1N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-fluorobenzyl)-4-methoxy-1-piperidinyl)benzenecarboximidamide

Example 1A 1-benzyl-4-(2-fluorobenzyl)-4-piperidinol

A suspension of Mg (3.50 g, 144 mmol) in diethyl ether (75 mL) wastreated with 2-fluorobenzyl chloride (19.0 g, 131 mmol), stirred untilall the Mg dissolved, treated with N-benzyl 4-piperidone (27.2 g, 144mmol) in RATIO THF/diethyl ether (40 mL), and stirred at roomtemperature until the reaction was complete by TLC analysis. The mixturewas partitioned between ethyl acetate and saturated NH₄Cl and theaqueous layer was extracted with ethyl acetate twice. The combinedorganic layers were dried (MgSO₄), filtered, and concentrated to give aresidue which was used without further purification. MS (ESI) m/e 300(M+H)⁺.

Example 1B 4-(2-fluorobenzyl)-4-piperidinol

A solution of EXAMPLE 1A (39.0 g, 131 mmol) in ethyl acetate (500 mL)was treated with Pd/C (3.90 g), stirred under hydrogen atmosphere (60psi) until the reaction was complete by TLC analysis, and filtered. Thefiltrate was concentrated to give a residue that was used withoutfurther purification. MS (ESI) m/e 210 (M+H)⁺.

Example 1C ethyl 4-(4-(2-fluorobenzyl)-4-hydroxy-1-piperidinyl)benzoate

A solution EXAMPLE 1B (13.75 g, 65.8 mmol) in DMSO (20 mL) was treatedwith ethyl 4-fluorobenzoate (8.50 g, 51.0 mmol) and K₂CO₃ (6.90 g, 50.0mmol) and was heated to 110° C. overnight. The suspension was filteredand the filtrate diluted with ethyl acetate, washed with water (2×),dried (MgSO₄), and filtered. Concentration of the filtrate gave aresidue that was purified by silica gel chromatography eluting with 30%ethyl acetate in hexanes to provide the desired product (17.89 g, 76%).MS (ESI) m/e 358 (M+H)⁺.

Example 1D ethyl 4-(4-(2-fluorobenzyl)-4-methoxy-1-piperidinyl)benzoate

A solution of EXAMPLE 1C (17.89 g, 50.1 mmol) in THF (150 mL) and HMPA(33 mL) was treated with NaH (4.0 g of a 60% dispersion, 100 mmol) at 0°C., stirred for 30 minutes, treated with CH₃I (20 mL, 321 mmol), andstirred overnight. The reaction mixture was partitioned between ethylacetate and saturated aqueous NH₄Cl. The organic layer was washed withwater (2×), dried (MgSO₄), and filtered. Filtration of the concentrateprovided the desired product which was used without furtherpurification. MS (ESI) m/e 372 (M+H)⁺.

Example 1E 4-(4-(2-fluorobenzyl)-4-methoxy-1-piperidinyl)benzoic acid

A solution of EXAMPLE 1D (20.54 g, 55.4 mmol) in dioxane (100 mL) wastreated with 1N NaOH (100 mL, 100 mmol), stirred overnight, acidifiedwith 1N HCl, extracted with ethyl acetate (3×), dried (MgSO₄), andfiltered. Concentration of the filtrate gave a residue that was purifiedby silica gel chromatography eluting with to provide the desired product(xx g, xx %). MS (ESI) m/e 344 (M+H)⁺.

Example 1F 4-(4-(2-fluorobenzyl)-4-methoxy-1-piperidinyl)benzamide

A solution of EXAMPLE 1E in dichloromethane (20 mL) was treated withoxalyl chloride (0.305 mL, 3.50 mmol) and a drop of DMF, stirred for 6hours at room temperature, and concentrated. The resulting residue wasdissolved in dichloromethane (20 mL), cooled to 0° C., treated withaqueous NH₃ (3 mL), stirred for 6 hours, and partitioned between ethylacetate and saturated aqueous sodium chloride. The organic layer wasseparated and the aqueous layer was extracted with ethyl acetate threetimes. The combined organic layers were dried (MgSO₄) and filtered.Concentration of the filtrate gave the desired product as a residue thatwas utilized directly in the next step without further purification. MS

Example 1G 4-(4-(2-fluorobenzyl)-4-methoxy-1-piperidinyl)benzonitrile

A solution of EXAMPLE 1F in acetonitrile (20 mL) at 0° C. was treatedwith DMF (0.543 mL, 7.02 mmol) and oxalyl chloride (0.561 mL, 6.43mmol), stirred for 5 minutes, treated with pyridine (1.04 mL, 12.866mmol), and stirred for another 50 minutes at 0° C. The reaction mixturewas partitioned between ethyl acetate and saturated aqueous NaHCO₃, theaqueous layer extracted with ethyl acetate three times and the combinedorganic layers dried (MgSO₄), filtered, and concentrated to give thedesired product as a residue that was utilized directly in the next stepwithout further purification. MS (ESI) m/e 325 (M+H)⁺.

Example 1H4-(4-(2-fluorobenzyl)-4-methoxy-1-piperidinyl)benzenecarboximidamide

A solution of EXAMPLE 1G in ethanol (20 mL) at 0° C. was treated withgaseous HCl for 10 minutes, allowed to warm to ambient temperature, andstirred overnight. The reaction mixture was concentrated to dryness, theresidue dissolved in methanol (20 mL), and the resulting solutiontreated with gaseous NH₃ for 10 minutes, stirred overnight, andconcentrated to dryness. The resulting residue was purified by silicagel chromatography eluting with 10% 2N NH₃/methanol in dichloromethaneto give the desired product. MS (ESI) m/e 342 (M+H)⁺.

Example 1I4-(4-(2-fluorobenzyl)-4-methoxy-1-piperidinyl)-N-((4-fluoro-3-nitrophenyl)sulfonyl)benzenecarboximidamide

A solution of EXAMPLE 1H (0.200 g, 0.587 mmol) in dichloromethane (5 mL)was treated with triethylamine (0.245 mL, 1.76 mmol) and4-fluoro-3-nitrobenzenesulfonyl chloride (prepared according to theprocedure described in U.S. patent application Ser. No. 09/957,256,0.169 g, 0.704 mmol), stirred overnight, and concentrated. The residuewas purified by silica gel chromatography eluting with 40% ethyl acetatein hexanes to provide the desired product. MS (ESI) m/e 543 (M+H)⁺.

Example 1J benzyl(1R)-3-(dimethylamino)-1-(hydroxymethyl)-3-oxopropylcarbamate

A solution of 3-(S)-((carbobenzyloxy)amino)-γ-butyrolactone (preparedaccording to the procedure described in McGarvey, G. J.; Williams, J.M.; Hiner, R. N.; Matsubara, Y.; Oh, T. J. Am. Chem. Soc. 1986, 108,4943-4952, 7.72 g, 32.8 mmol) in THF (100 mL) was saturated with gaseousdimethylamine, stirred at room temperature for 16 hours, andconcentrated. The residue was filtered through a plug of silica geleluting with 50% acetone in hexanes to give the desired product (9.16 g,99%). MS (CI) m/e 281 (M+H)⁺.

Example 1K benzyl(1R)-3-(dimethylamino)-3-oxo-1-((phenylsulfanyl)methyl)propylcarbamate

A solution of EXAMPLE 1J (8.45 g, 30.14 mmol) in toluene (15 mL) wastreated with tributylphosphine (9.76 mL, 39.20 mmol), diphenyldisulfide(7.30 g, 39.20 mmol) and heated to 80° C. for 16 hours. The reactionmixture was concentrated and purified by column chromatography on silicagel eluting with a gradient of 0-50% ethyl acetate in hexanes to givethe desired product (10.62 g, 95%). MS (CI) m/e 373 (M+H)⁺.

Example 1L (3R)-3-amino-N,N-dimethyl-4-(phenylsulfanyl)butanamide

A suspension of EXAMPLE 1K (10.60 g, 28.46 mmol) in 50 mL 30% HBr/aceticacid was stirred at room temperature overnight. The resultinghomogeneous reaction mixture was concentrated, diluted with water (200mL) and 5% HCl (100 mL), and washed with diethyl ether (3×). The aqueousphase was adjusted to pH ˜8-9 with solid Na₂CO₃ and extracted withdichloromethane (5×). The combined organic phases were dried (MgSO₄),filtered, and concentrated to give the desired product (6.54 g, 96%). MS(CI) m/e 239 (M+H)⁺.

Example 1M N-((3R)-3-amino-4-(phenylsulfanyl)butyl)-N,N-dimethylamine

A solution of EXAMPLE 1L (8.68 g, 36.5 mmol) in THF (200 mL) was treatedwith BH₃-dimethylsulfide (18.2 mL, 182.5 mmol) at room temperature,stirred overnight, treated slowly with methanol (20 mL), followed by 2NHCl (50 mL), stirred overnight, and concentrated. The resulting residuewas purified by silica gel chromatography eluting with 5% 7N NH₃/CH₃OHin dichloromethane to give the desired product (4.50 g, 55%). MS (CI)m/e 224 (M+H)⁺.

Example 1NN-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-fluorobenzyl)-4-methoxy-1-piperidinyl)benzenecarboximidamide

A solution of EXAMPLE 1I (0.072 g, 0.132 mmol) in 1:1DMSO/diisopropylethylamine (2 mL) was treated with EXAMPLE 1M (0.044 g,0.199 mmol) at room temperature, stirred overnight, and concentrated.The resulting residue was purified by silica gel chromatography elutingwith 5% 2N NH₃/CH₃OH in dichloromethane to provide the desired product(0.072 g, 73%). MS (ESI) m/e 747 (M−H)⁻; ¹H NMR (400 MHz, DMSO-d₆) δ8.74 (s, 1H), 8.58 (d, 1H), 8.39 (d, 1H), 7.95 (s, 1H), 7.73 (m, 3H),7.20 (m, 3H), 7.12 (t, 2H), 7.06 (m, 3H), 6.98 (d, 1H), 6.87 (d, 2H),4.05 (m, 1H), 3.58 (d, 2H), 3.29 (m, 4H), 3.22 (s, 3H), 2.92 (t, 2H),2.75 (s, 2H), 2.34 (m, 1H), 2.15 (m, 1H), 2.05 (s, 6H), 1.88 (m, 1H),1.75 (m, 1H), 1.65 (d, 2H), 1.44 (m, 2H).

Example 2N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4,4-dimethyl-1-piperidinyl)benzenecarboximidamide

Example 2A 4-(4,4-dimethyl-1-piperidinyl)benzamide

The desired product was prepared by substituting4-(4,4-dimethylpiperidin-1-yl)benzoic acid (prepared according to theprocedure described in commonly owned U.S. patent application Ser. No.09/957,256, filed Sep. 20, 2001) for EXAMPLE 1E in EXAMPLE 1F. MS

Example 2B 4-(4,4-dimethyl-1-piperidinyl)benzonitrile

The desired product was prepared by substituting EXAMPLE 2A for EXAMPLE1F in EXAMPLE 1G. MS (ESI) m/e 215 (M+H)⁺.

Example 2C 4-(4,4-dimethyl-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 2B for EXAMPLE1G in EXAMPLE 1H. MS (ESI) m/e 232 (M+H)⁺.

Example 2D4-(4,4-dimethyl-1-piperidinyl)-N-((4-fluoro-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 2C for EXAMPLE1H in EXAMPLE 1I. MS (ESI) m/e 435 (M+H)⁺.

Example 2EN-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4,4-dimethyl-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 2D for EXAMPLE1I in EXAMPLE 1N. MS (ESI) m/e 639 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ8.76 (s, 1H), 8.60 (d, 1H), 8.43 (d, 1H), 7.98 (s, 1H), 7.78 (d, 2H),7.28 (m, 2H), 7.14 (m, 3H), 7.04 (d, 1H), 6.93 (d, 2H), 4.11 (m, 1H),3.35 (m, 6H), 2.40 (m, 1H), 2.24 (m, 1H), 2.12 (s, 6H), 1.94 (m, 1H),1.80 (m, 1H), 1.38 (m, 4H), 0.95 (s, 6H).

Example 3N-((4-(((1R)-5-(dimethylamino)-1-((phenylsulfanyl)methyl)pentyl)amino)-3-nitrophenyl)sulfonyl)-4-(4,4-dimethyl-1-piperidinyl)benzenecarboximidamide

Example 3A N-((5R)-5-amino-6-(phenylsulfanyl)hexyl)-N,N-dimethylamine

The desired product was prepared by substituting(5R)-5-amino-N,N-dimethyl-6-(phenylsulfanyl)hexanamide for EXAMPLE 1L inEXAMPLE 1M. MS (ESI) m/e 253 (M+H)⁺.

Example 3BN-((4-(((1R)-5-(dimethylamino)-1-((phenylsulfanyl)methyl)pentyl)amino)-3-nitrophenyl)sulfonyl)-4-(4,4-dimethyl-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 3A and EXAMPLE2D for EXAMPLE 1L and EXAMPLE 1I, respectively in EXAMPLE 1N. MS (ESI)m/e 667 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.84 (s, 1H), 8.42 (d, 1H),8.23 (d, 1H), 7.98 (s, 1H), 7.80 (d, 2H), 7.25 (m, 2H), 7.12 (m, 3H),6.94 (d, 2H), 4.08 (m, 1H), 3.59 (m, 2H), 3.11 (m, 2H), 2.92 (m, 2H),2.66 (s, 6H), 1.37 (m, 4H).

Example 44-(4,4-dimethyl-1-piperidinyl)-N-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting2-phenylsulfanylethylamine and EXAMPLE 2D for EXAMPLE 1L and EXAMPLE 1I,respectively in EXAMPLE 1N.

MS (ESI) m/e 568 (M+H)⁺; ¹H NMR (500 MHz, CD₃OD) δ 8.61 (d, 1H), 7.87(dd, 1H), 7.76 (d, 2H), 7.35 (d, 2H), 7.18 (t, 2H), 7.13 (t, 1H), 7.01(d, 1H), 6.92 (d, 2H), 5.48 (s, 1H), 4.06 (t, 1H), 3.65 (t, 2H), 3.65(t, 2H), 3.36 (m, 4H), 3.25 (t, 2H), 1.48 (m, 4H), 1.00 (s, 6H).

Example 54-(4-benzyl-4-methoxy-1-piperidinyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide

Example 5A 4-(4-benzyl-4-hydroxy-1-piperidinyl)benzonitrile

A solution of benzylmagnesium chloride (1.90 mL of a 2M solution in THF,3.80 mmol) at −78° C. was treated with4-(4-oxo-1-piperidinyl)benzonitrile (prepared according to the proceduredescribed in Synthesis 1981, 606-608, 0.30 g, 1.51 mmol), and wasallowed to warm to room temperature overnight. The reaction mixture waspartitioned between ethyl acetate and saturated aqueous NH₄Cl and theaqueous layer was extracted with ethyl acetate (2×). The combinedorganic layers were dried (MgSO₄), filtered, and concentrated. Theresulting residue was purified by silica gel chromatography eluting with20% ethyl acetate in hexanes to give the desired product (0.087 g, 20%).MS (ESI) m/e 293 (M+H)⁺.

Example 5B 4-(4-benzyl-4-methoxy-1-piperidinyl)benzonitrile

The desired product was prepared by substituting EXAMPLE 5A for EXAMPLE1C in EXAMPLE 1D. MS (ESI) m/e (M+H)⁺.

Example 5C 4-(4-benzyl-4-methoxy-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 5B for EXAMPLE1G in EXAMPLE 1H. MS (ESI) m/e (M+H)⁺.

Example 5D4-(4-benzyl-4-methoxy-1-piperidinyl)-N-((4-fluoro-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 5C for EXAMPLE1H in EXAMPLE 1I. MS (ESI) m/e (M+H)⁺.

Example 5E4-(4-benzyl-4-methoxy-1-piperidinyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 5D for EXAMPLE1I in EXAMPLE 1N. MS (ESI) m/e 731 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ8.76 (s, 1H), 8.60 (d, 1H), 8.43 (d, 1H), 7.98 (s, 1H), 7.78 (m, 3H),7.27 (m, 4H), 7.16 (m, 5H), 7.04 (d, 1H), 6.92 (d, 2H), 4.11 (m, 1H),3.62 (d, 1H), 3.36 (m, 2H), 3.28 (s, 3H), 3.01 (m, 2H), 2.78 (s, 2H),2.40 (m, 1H), 2.22 (m, 1H), 2.11 (s, 6H), 1.93 (m, 1H), 1.82 (m, 1H),1.67 (d, 2H), 1.48 (m, 2H).

Example 64-(4-(cyclohexylmethyl)-4-methoxy-1-piperidinyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide

Example 6A 4-(4-(cyclohexylmethyl)-4-hydroxy-1-piperidinyl)benzonitrile

The desired product was prepared by substitutingcyclohexylmethylmagnesium bromide for benzylmagnesium chloride inEXAMPLE 5A. MS (ESI) m/e 299 (M+H)⁺.

Example 6B 4-(4-(cyclohexylmethyl)-4-methoxy-1-piperidinyl)benzonitrile

The desired product was prepared by substituting EXAMPLE 6A for EXAMPLE1C in EXAMPLE 1D. MS.

Example 6C4-(4-(cyclohexylmethyl)-4-methoxy-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 6B for EXAMPLE1G in EXAMPLE 1H. MS.

Example 6D4-(4-(cyclohexylmethyl)-4-methoxy-1-piperidinyl)-N-((4-fluoro-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 6C for EXAMPLE1H in EXAMPLE 1I. MS

Example 6E4-(4-(cyclohexylmethyl)-4-methoxy-1-piperidinyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 6D for EXAMPLE1I in EXAMPLE 1N. MS (ESI) m/e 737 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ8.77 (s, 1H), 8.61 (d, 1H), 8.42 (d, 1H), 7.98 (s, 1H), 7.78 (d, 3H),7.27 (d, 2H), 7.13 (m, 3H), 7.04 (d, 1H), 6.93 (d, 2H), 4.10 (m, 1H),3.58 (d, 2H), 3.36 (m, 2H), 3.07 (s, 3H), 3.03 (m, 2H), 2.39 (m, 1H),2.20 (m, 1H), 2.10 (s, 6H), 1.95 (m, 1H), 1.80 (m, 5H), 1.60 (m, 3H),1.45 (m, 3H), 1.31 (d, 2H), 1.15 (m, 3H), 0.96 (m, 2H).

Example 74-(4-(2,4-difluorobenzyl)-4-methoxy-1-piperidinyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide

Example 7A4-(4-(2,4-difluorobenzyl)-4-hydroxy-1-piperidinyl)benzonitrile

The desired product was prepared by substituting2,4-difluorobenzylmagnesium bromide for benzylmagnesium chloride inEXAMPLE 5A. MS (ESI) m/e 329 (M+H)⁺.

Example 7B4-(4-(2,4-difluorobenzyl)-4-methoxy-1-piperidinyl)benzonitrile

The desired product was prepared by substituting EXAMPLE 7A for EXAMPLE1C in EXAMPLE 1D. MS

Example 7C4-(4-(2,4-difluorobenzyl)-4-methoxy-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 7B for EXAMPLE1G in EXAMPLE 1H. MS

Example 7D4-(4-(2,4-difluorobenzyl)-4-methoxy-1-piperidinyl)-N-((4-fluoro-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 7C for EXAMPLE1H in EXAMPLE 1I. MS

Example 7E4-(4-(2,4-difluorobenzyl)-4-methoxy-1-piperidinyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 7D for EXAMPLE1I in EXAMPLE 1N. MS (ESI) m/e 767 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ8.77 (s, 1H), 8.62 (d, 1H), 8.43 (d, 1H), 7.98 (s, 1H), 7.78 (m, 3H),7.28 (m, 3H), 7.14 (m, 3H), 7.02 (m, 2H), 6.93 (d, 2H), 4.11 (m, 1H),3.64 (d, 2H), 3.36 (m, 2H), 3.26 (s, 3H), 2.99 (m, 2H), 2.79 (s, 2H),2.38 (m, 1H), 2.20 (m, 1H), 2.08 (s, 6H), 1.94 (m, 1H), 1.81 (m, 1H),1.69 (d, 2H), 1.49 (m, 2H).

Example 8N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-methoxy-4-(2-methylbenzyl)-1-piperidinyl)benzenecarboximidamide

Example 8A 4-(4-hydroxy-4-(2-methylbenzyl)-1-piperidinyl)benzonitrile

The desired product was prepared by substituting 2-methylbenzylmagnesiumbromide for benzylmagnesium chloride in EXAMPLE 5A. MS (ESI) m/e 307(M+H)⁺.

Example 8B 4-(4-methoxy-4-(2-methylbenzyl)-1-piperidinyl)benzonitrile

The desired product was prepared by substituting EXAMPLE 8A for EXAMPLE1C in EXAMPLE 1D. MS

Example 8C4-(4-methoxy-4-(2-methylbenzyl)-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 8B for EXAMPLE1G in EXAMPLE 1H. MS

Example 8DN-((4-fluoro-3-nitrophenyl)sulfonyl)-4-(4-methoxy-4-(2-methylbenzyl)-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 8C for EXAMPLE1H in EXAMPLE 1I. MS

Example 8EN-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-methoxy-4-(2-methylbenzyl)-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 8D for EXAMPLE1I in EXAMPLE 1L. MS (ESI) m/e 745 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ8.75 (s, 1H), 8.61 (d, 1H), 8.42 (d, 1H), 7.97 (s, 1H), 7.77 (m, 3H),7.27 (m, 2H), 7.11 (m, 7H), 6.91 (d, 2H), 4.10 (m, 1H), 3.64 (d, 2H),3.36 (m, 2H), 3.28 (s, 3H), 2.96 (m, 2H), 2.80 (s, 2H), 2.39 (m, 1H),2.27 (s, 3H), 2.20 (m, 1H), 2.10 (s, 6H), 1.93 (m, 1H), 1.79 (m, 3H),1.49 (m, 2H).

Example 9N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(4-fluorobenzylidene)-1-piperidinyl)benzenecarboximidamide

Example 9A 4-(4-(4-fluorobenzylidene)-1-piperidinyl)benzonitrile

A suspension of the 4-fluorobenzyl triphenylphosphonium chloride (0.737g, 1.81 mmol) in THF (10 mL) was treated with nBuLi (724 μL of a 1.6Msolution in hexanes, 1.81 mmol) at 0° C., treated with1-(4′-cyanophenyl)-4-oxopiperidine (prepared according to the proceduredescribed in Synthesis 1981, 606-608, 0.300 g, 1.51 mmol), and graduallywarmed to room temperature overnight. The reaction mixture waspartitioned between ethyl acetate and saturated aqueous NH₄Cl and theaqueous layer was extracted with ethyl acetate (2×). The combinedorganic layers were dried (MgSO₄), filtered, and concentrated. Theresulting residue was purified by silica gel chromatography eluting with10% ethyl acetate in hexanes to give the desired product. (0.268 g,61%). MS (ESI) m/e 292 (M+H)⁺.

Example 9B4-(4-(4-fluorobenzylidene)-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 9A for EXAMPLE1G in EXAMPLE 1H. MS

Example 9C4-(4-(4-fluorobenzylidene)-1-piperidinyl)-N-((4-fluoro-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 9B for EXAMPLE1H in EXAMPLE 1I. MS

Example 9DN-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(4-fluorobenzylidene)-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 9C for EXAMPLE1I in EXAMPLE 1N. MS (ESI) m/e 717 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ8.78 (s, 1H), 8.61 (d, 1H), 8.44 (d, 1H), 8.00 (d, 1H), 7.80 (m, 3H),7.27 (m, 4H), 7.15 (m, 5H), 7.05 (d, 1H), 6.97 (d, 2H), 6.37 (s, 1H),4.11 (m, 1H), 3.51 (m, 2H), 3.43 (m, 2H), 3.36 (m, 2H), 2.50 (m, 2H),2.39 (m, 3H), 2.21 (m, 1H), 2.11 (s, 6H), 1.94 (m, 1H), 1.80 (m, 1H).

Example 10N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-(trifluoromethyl)benzylidene)-1-piperidinyl)benzenecarboximidamide

Example 10A4-(4-(2-(trifluoromethyl)benzylidene)-1-piperidinyl)benzonitrile

The desired product was prepared by substituting2-(trifluoromethyl)benzyl triphenylphosphonium bromide (preparedaccording to the procedure described in J. Chem. Soc. Perkin Trans. I1995, 18, 2293-2308) for 4-fluorobenzyl triphenylphosphoniumchloride inEXAMPLE 9A. MS (ESI) m/e 343 (M+H)⁺.

Example 10B4-(4-(2-(trifluoromethyl)benzylidene)-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 10A for EXAMPLE1G in EXAMPLE 1H. MS

Example 10CN-((4-fluoro-3-nitrophenyl)sulfonyl)-4-(4-(2-(trifluoromethyl)benzylidene)-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 10B for EXAMPLE1H in EXAMPLE 1I. MS

Example 10DN-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-(trifluoromethyl)benzylidene)-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 10C for EXAMPLE1I in EXAMPLE 1N. MS (ESI) m/e 765 (M−H)⁻; ¹H NMR (400 MHz, DMSO-d₆) δ8.79 (s, 1H), 8.62 (d, 1H), 8.44 (d, 1H), 8.01 (s, 1H), 7.79 (m, 3H),7.73 (d, 1H), 7.64 (t, 1H), 7.47 (t, 1H), 7.36 (d, 1H), 7.28 (m, 2H),7.14 (m, 3H), 7.04 (d, 1H), 6.98 (d, 1H), 6.50 (s, 1H), 4.12 (m, 1H),3.51 (m, 2H), 3.36 (m, 4H), 2.40 (m, 3H), 2.22 (m, 3H), 2.10 (s, 6H),1.93 (m, 1H), 1.80 (m, 1H).

Example 11N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(3-thienylmethylene)-1-piperidinyl)benzenecarboximidamide

Example 11A 4-(4-(3-thienylmethylene)-1-piperidinyl)benzonitrile

The desired product was prepared by substitutingthiophen-3-ylmethyltriphenyl phosphonium bromide for 4-fluorobenzyltriphenylphosphonium chloride in EXAMPLE 9A. MS

Example 11B4-(4-(3-thienylmethylene)-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 11A for EXAMPLE1G in EXAMPLE 1H. MS

Example 11CN-((4-fluoro-3-nitrophenyl)sulfonyl)-4-(4-(3-thienylmethylene)-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 11B for EXAMPLE1I in EXAMPLE 1N. MS

Example 11DN-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(3-thienylmethylene)-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 11C for EXAMPLE1I in EXAMPLE 1N. MS (ESI) m/e 705 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ8.78 (s, 1H), 8.61 (d, 1H), 8.43 (d, 1H), 7.99 (s, 1H), 7.81 (d, 2H),7.78 (d, 1H), 7.51 (dd, 1H), 7.32 (m, 1H), 7.28 (m, 2H), 7.13 (m, 4H),7.04 (d, 1H), 6.95 (d, 2H), 6.32 (s, 1H), 4.11 (m, 1H), 3.48 (m, 4H),3.37 (m, 2H), 2.58 (t, 2H), 2.39 (m, 3H), 2.21 (m, 1H), 2.11 (s, 6H),1.93 (m, 1H), 1.81 (m, 1H).

Example 12N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(3,3-diphenyl-2-propenyl)-1-piperazinyl)benzenecarboximidamide

Example 12A 4-(4-(3,3-diphenyl-2-propenyl)-1-piperazinyl)benzonitrile

A suspension of 4-piperazin-1-ylbenzonitrile hydrochloride (1.30 g, 5.00mmol) and 3,3-diphenylacrylaldehyde (1.56 g, 7.50 mmol)) indichloromethane (10 mL) and methanol (10 mL) was neutralized to pH 5with diisopropylethylamine, treated with polymer-supportedcyanoborohydride (2.47 mmol/g, 6 g, 14.82 mmol), shaken at roomtemperature for 24 hours, and filtered. The resin was washed with 1:1dichloromethane/methanol (10 mL×3) and the combined filtrates wereconcentrated. The concentrate was purified by silica gel chromatographyeluting with a gradient from 10%-50% ethyl acetate/hexanes to providethe desired product (1.60 g, 84%). MS (CI) m/e 380 (M+H)⁺.

Example 12B4-(4-(3,3-diphenyl-2-propenyl)-1-piperazinyl)benzenecarboximidamide

A solution of EXAMPLE 12A (0.515 g, 1.36 mmol) in dry tetrahydrofuran (6mL) was treated dropwise with LiHMDS (1M, 6.8 mL, 6.8 mmol), stirred for16 hours, quenched with 1N HCl (8 mL), and filtered. The filter cake wascollected to provide the desired product (0.45 g, 71%) that was usedwithout further purification. MS (CI) m/e 397 (M+H)⁺.

Example 12CN-((4-chloro-3-nitrophenyl)sulfonyl)-4-(4-(3,3-diphenyl-2-propenyl)-1-piperazinyl)benzenecarboximidamide

A suspension of EXAMPLE 12B (0.421 g, 0.897 mmol) anddiisopropylethylamine (0.50 mL) in dichloromethane (5 mL) was treatedwith 4-chloro-3-nitrobenzenesulfonyl chloride (0.252 g, 0.99 mmol),stirred at room temperature for 24 hours and concentrated. The resultingresidue was purified by silica gel chromatography eluting with agradient from 0%-10% methanol/dichloromethane to give the desiredproduct (0.33 g, 60%). MS (ESI) m/e 614 (M−H)⁻.

Example 12DN-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(3,3-diphenyl-2-propenyl)-1-piperazinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 12C for EXAMPLE1I in EXAMPLE 1N. MS (ESI) m/e 802 (M−H)⁻; ¹H NMR (500 MHz, DMSO-d₆) δ10.32 (br s, 1H), 9.64 (s, 1H), 8.90 (s, 1H), 8.44 (d, 1H), 8.20 (d,1H), 8.09 (s, 1H), 7.83 (m, 3H), 7.47 (t, 2H), 7.42 (m, 1H), 7.37 (m,3H), 7.26 (m, 4H), 7.17 (m, 3H), 7.14 (d, 2H), 7.11 (m, 2H), 7.02 (d,2H), 6.27 (t, 1H), 4.16 (m, 1H), 4.02 (br s, 1H), 3.85 (d, 2H), 3.54 (brs, 1H), 3.12 (m, 6H), 2.74 (s, 6H), 2.14 (q, 2H).

Example 134-(4-benzyl-4-methoxycyclohexyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-1-piperazinecarboximidamide

Example 13A methyl4-(4-benzyl-4-methoxycyclohexyl)-N-cyano-1-piperazinecarbimidothioate

A solution of 1-(4-benzyl-4-methoxycyclohexyl)piperazine (preparedaccording to the procedure described in commonly owned U.S. patentapplication Ser. No. 10/269,739, filed Oct. 14, 2002, 0.052 g, 0.181mmol) in dichloromethane (5 mL) was treated with dimethylcyanothioiminocarbonate (0.026 mg, 0.181 mmol), heated to 40° C.overnight and concentrated. The crude material was used without furtherpurification. MS.

Example 13B4-(4-benzyl-4-methoxycyclohexyl)-N-cyano-N′-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-1-piperazinecarboximidamide

A solution of the EXAMPLE 13A (0.070 g, 0.181 mmol) in methanol (4.5 mL)and water (0.5 mL) was treated with4-(((1R)-3-(dimethylamino)-1-((phenylthio)methyl)propyl)amino)-3-nitrobenzenesulfonamide(prepared according to the procedure described in commonly owned U.S.patent application Ser. No. 09/957,256, filed Sep. 20, 2001, 0.069 g,0.181 mmol) and NaOH (0.022 g, 0.543 mmol) and was heated to 50° C.overnight. The solution was partitioned between dichloromethane andsaturated NaHCO₃. The organic layer was separated and the aqueous layerwas extracted with dichloromethane three times. The combined organiclayers were dried (MgSO₄), filtered, and concentrated. The resultingresidue was purified by C18 reverse phase HPLC eluting with a gradientfrom 10-100% acetonitrile in 0.1% aqueous TFA to give the desiredproduct. MS

Example 13C4-(4-benzyl-4-methoxycyclohexyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-1-piperazinecarboximidamide

A solution of EXAMPLE 13B (0.020 g, 0.026 mmol) in 2N HCl (1 mL) andCH₃OH (1 mL) was heated to 50° C. overnight and concentrated. Theresulting residue was purified by C18 reverse phase HPLC eluting with agradient from 10-100% acetonitrile in 0.1% aqueous TFA to give thedesired product (0.0084 g, 42%). MS; ¹H NMR (300 MHz, CD₃OD) δ 8.44 (m,1H), 7.74 (m, 1H), 7.22 (m, 10H), 6.97 (m, 1H), 4.12 (m, 1H), 3.45 (m,10H), 3.30 (s, 3H), 3.25 (m, 1H), 3.13 (s, 6H), 2.74 (m, 2H), 2.56 (m,3H), 2.32 (m, 3H), 1.52 (m, 10H).

Example 14N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-phenyl-1-piperazinecarboximidamide

Example 14A methyl N-cyano-4-phenyl-1-piperazinecarbimidothioate

The desired product was prepared by substituting 1-phenylpiperazine for1-(4-benzyl-4-methoxycyclohexyl)piperazine in EXAMPLE 13A. MS

Example 14BN-cyano-N′-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-phenyl-1-piperazinecarboximidamide

The desired product was obtained by substituting EXAMPLE 14A for EXAMPLE13A in EXAMPLE 13B. MS

Example 14CN-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-phenyl-1-piperazinecarboximidamide

The desired product was obtained by substituting EXAMPLE 14B for EXAMPLE13B in EXAMPLE 13C. MS; ¹H NMR (300 MHz, CD₃OD) δ 8.47 (d, 1H), 7.76(dd, 1H), 7.25 (m, 4H), 7.14 (m, 3H), 6.96 (m, 3H), 6.86 (t, 1H), 4.12(m, 1H), 3.71 (m, 4H), 3.44 (m, 4H), 3.16 (m, 4H), 3.12 (s, 6H), 2.36(m, 2H).

Example 15N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-methoxy-4-(2-methylbenzyl)cyclohexyl)-1-piperazinecarboximidamide

Example 15A 8-(2-methylbenzyl)-1,4-dioxaspiro(4.5)decan-8-ol

A solution of 2-methylbenzyl chloride (0.579 g, 4.12 mmol) in THF (20mL) was treated with Mg (0.180 g, 7.50 mmol) and stirred at roomtemperature until all the Mg had dissolved. The mixture was cooled to 0°C., treated with a solution of 1,4-cyclohexanedione mono-ethylene ketal(0.579 g, 4.12 mmol) in THF (50 mL), warmed to room temperature, stirredovernight, quenched with saturated NH₄Cl (100 mL), and extracted withethyl acetate (3×100 mL). The combined extracts were washed with waterand brine, dried (Na₂SO₄), filtered, and concentrated. The concentratewas purified by flash column chromatography on silica gel with 6:1hexanes/ethyl acetate to provide the desired product (0.48 g, 44%) MS(ESI) m/e 262 (M+H)⁺.

Example 15B 8-methoxy-8-(2-methylbenzyl)-1,4-dioxaspiro(4.5)decane

The desired product was obtained by substituting EXAMPLE 15A for EXAMPLE1C in EXAMPLE 1D. MS (ESI) m/e 294 (M+NH₄)⁺.

Example 15C 4-methoxy-4-(2-methylbenzyl)cyclohexanone

A solution of EXAMPLE 15B (0.51 g, 1.80 mmol) in acetone (10 mL) wastreated with water (5 mL) and p-toluenesulfonic acid monohydrate (0.20g), heated to reflux, stirred overnight, and concentrated to remove theacetone. The remaining aqueous solution was extracted with ethyl acetate(3×100 mL) and the combined extracts were washed sequentially with 1NNaOH, water, and brine, dried (Na₂SO₄), filtered, and concentrated toprovide the desired product (0.42 g, 100%). MS (ESI) m/e 233 (M+H)⁺.

Example 15D tert-butyl4-(4-methoxy-4-(2-methylbenzyl)cyclohexyl)-1-piperazinecarboxylate

A solution of EXAMPLE 15C (0.42 g, 1.80 mmol) and1-tert-butoxycarbonylpiperazine (0.391 g, 2.10 mmol) in dichloroethane(10 mL) at room temperature was treated with acetic acid (500 μL) andsodium triacetoxyborohydride (10.89 g, 4.2 mmol), stirred overnight,diluted with ethyl acetate (300 mL), washed sequentially with 1N NaOH,water, and brine, dried (Na₂SO₄), filtered, and concentrated to providethe desired product (0.51 g, 70%); MS (ESI) m/e 403 (M+H)⁺.

Example 15E 1-(4-methoxy-4-(2-methylbenzyl)cyclohexyl)piperazine

A solution of EXAMPLE 15D (0.51 g, 1.26 mmol) in dichloromethane (5 mL)at room temperature was treated with 2M HCl in diethyl ether (5 mL),stirred overnight, and concentrated to provide the desired product (0.38g, 100%). MS (ESI) m/e 303 (M+H)⁺.

Example 15F methylN-cyano-4-(4-methoxy-4-(2-methylbenzyl)cyclohexyl)-1-piperazinecarbimidothioate

The desired product was prepared by substituting EXAMPLE 15E for1-(4-benzyl-4-methoxycyclohexyl)piperazine in EXAMPLE 13A. MS

Example 15GN-cyano-N′-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-methoxy-4-(2-methylbenzyl)cyclohexyl)-1-piperazinecarboximidamide

The desired product was obtained by substituting EXAMPLE 15F for EXAMPLE13A in EXAMPLE 13B. MS

Example 15HN-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-methoxy-4-(2-methylbenzyl)cyclohexyl)-1-piperazinecarboximidamide

The desired product was obtained by substituting EXAMPLE 15G for EXAMPLE13B in EXAMPLE 13C. MS; ¹H NMR (300 MHz, CD₃OD) δ 8.46 (d, 1H), 8.21 (d,1H), 7.76 (dd, 1H), 7.29 (m, 2H), 7.12 (m, 6H), 6.97 (d, 1H), 4.13 (m,1H), 3.37 (m, 12H), 3.15 (m, 8H), 2.85 (m, 2H), 2.34 (m, 5H), 1.30-2.0(m, 10H).

Example 164-(4-(2-chlorobenzyl)-4-methoxycyclohexyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-1-piperazinecarboximidamide

Example 16A 8-(2-chlorobenzyl)-1,4-dioxaspiro(4.5)decan-8-ol

The desired product was prepared by substituting 2-chlorobenzylbromidefor 2-methylbenzyl chloride in EXAMPLE 15A. MS (ESI) m/e 300 (M+H)⁺.

Example 16B 8-(2-chlorobenzyl)-8-methoxy-1,4-dioxaspiro(4.5)decane

The desired product was prepared by substituting EXAMPLE 16A for EXAMPLE1C in EXAMPLE 1D. MS (ESI) m/e 332 (M+NH₄)⁺.

Example 16C 4-(2-chlorobenzyl)-4-methoxycyclohexanone

The desired product was prepared by substituting EXAMPLE 16B for EXAMPLE15B in EXAMPLE 15C. MS (ESI) m/e 270 (M+NH₄)⁺.

Example 16D tert-butyl4-(4-(2-chlorobenzyl)-4-methoxycyclohexyl)-1-piperazinecarboxylate

The desired product was prepared by substituting EXAMPLE 16C for EXAMPLE15C in EXAMPLE 15D. MS (ESI) m/e 423 (M+H)⁺.

Example 16E 1-(4-(2-chlorobenzyl)-4-methoxycyclohexyl)piperazine

The desired product was prepared by substituting EXAMPLE 16D for EXAMPLE15D in EXAMPLE 15E. MS (ESI) m/e 323 (M+H)⁺.

Example 16F methyl4-(4-(2-chlorobenzyl)-4-methoxycyclohexyl)-N-cyano-1-piperazinecarbimidothioate

The desired product was prepared by substituting EXAMPLE 16E for1-(4-benzyl-4-methoxycyclohexyl)piperazine in EXAMPLE 13A. MS

Example 16G4-(4-(2-chlorobenzyl)-4-methoxycyclohexyl)-N-cyano-N′-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-1-piperazinecarboximidamide

The desired product was prepared by substituting EXAMPLE 16F for EXAMPLE13A in EXAMPLE 13B. MS

Example 16H4-(4-(2-chlorobenzyl)-4-methoxycyclohexyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-1-piperazinecarboximidamide

The desired product was prepared by substituting EXAMPLE 16G for EXAMPLE13B in EXAMPLE 13C. MS; ¹H NMR (300 MHz, CD₃OD) δ 8.46 (d, 1H), 8.21 (d,1H), 7.76 (m, 1H), 7.35 (m, 1H), 7.29 (m, 3H), 7.19 (m, 4H), 6.98 (m,1H), 4.14 (m, 1H), 3.45 (m, 3H), 3.35 (s, 3H), 3.21 (m, 3H), 3.13 (m,7H), 3.03 (m, 6H), 2.34 (m, 2H), 1.68 (m, 10H).

Example 17N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-fluorobenzyl)-4-methoxycyclohexyl)-1-piperazinecarboximidamide

Example 17A 8-(2-fluorobenzyl)-1,4-dioxaspiro(4.5)decan-8-ol

The desired product was prepared by substituting 2-fluorobenzyl bromidefor 2-methylbenzyl chloride in EXAMPLE 15A. MS (ESI) m/e 284 (M+NH₄)⁺.

Example 17B 8-(2-fluorobenzyl)-8-methoxy-1,4-dioxaspiro(4.5)decane

The desired product was prepared by substituting EXAMPLE 17A for EXAMPLE1C in EXAMPLE 1D. MS (ESI) m/e 298 (M+NH₄)⁺.

Example 17C 4-(2-fluorobenzyl)-4-methoxycyclohexanone

The desired product was prepared by substituting EXAMPLE 16B for EXAMPLE15B in EXAMPLE 15C. MS (ESI) m/e 254 (M+NH₄)⁺.

Example 17D tert-butyl4-(4-(2-fluorobenzyl)-4-methoxycyclohexyl)-1-piperazinecarboxylate

The desired product was prepared by substituting EXAMPLE 17C for EXAMPLE15C in EXAMPLE 15D. MS (ESI) m/e 407 (M+H)⁺.

Example 17E 1-(4-(2-fluorobenzyl)-4-methoxycyclohexyl)piperazine

The desired product was prepared by substituting EXAMPLE 17D for EXAMPLE15D in EXAMPLE 15E. MS (ESI) m/e 307 (M+H)⁺.

Example 17F methylN-cyano-4-(4-(2-fluorobenzyl)-4-methoxycyclohexyl)-1-piperazinecarbimidothioate

The desired product was prepared by substituting EXAMPLE 17E for1-(4-benzyl-4-methoxycyclohexyl)piperazine in EXAMPLE 13A. MS

Example 17GN-cyano-N′-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-fluorobenzyl)-4-methoxycyclohexyl)-1-piperazinecarboximidamide

The desired product was prepared by substituting EXAMPLE 17F for EXAMPLE13A in EXAMPLE 13B. MS

Example 17HN-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-fluorobenzyl)-4-methoxycyclohexyl)-1-piperazinecarboximidamide

The desired product was prepared by substituting EXAMPLE 17G for EXAMPLE13B in EXAMPLE 13C. MS; ¹H NMR (300 MHz, CD₃OD) δ 8.48 (m, 1H), 8.22 (d,1H), 7.77 (m, 1H), 7.30 (m, 2H), 7.20 (m, 4H), 7.03 (m, 3H), 4.14 (m,1H), 3.45 (m, 6H), 3.34 (s, 3H), 3.24 (m, 5H), 3.13 (s, 6H), 2.86 (d,2H), 2.32 (m, 2H), 1.73 (m, 10H).

Example 184-(4-(2-bromobenzyl)-4-methoxycyclohexyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-1-piperazinecarboximidamide

Example 18A 8-(2-bromobenzyl)-1,4-dioxaspiro(4.5)decan-8-ol

The desired product was prepared by substituting 2-bromobenzyl bromidefor 2-methylbenzyl chloride in EXAMPLE 15A. MS (ESI) m/e 328 (M+H)⁺.

Example 18B 8-(2-bromobenzyl)-8-methoxy-1,4-dioxaspiro(4.5)decane

The desired product was prepared by substituting EXAMPLE 18A for EXAMPLE1C in EXAMPLE 1D. MS (ESI) m/e 360 (M+NH₄)⁺.

Example 18C 4-(2-bromobenzyl)-4-methoxycyclohexanone

The desired product was prepared by substituting EXAMPLE 18B for EXAMPLE15B in EXAMPLE 15C. MS (ESI) m/e 315 (M+NH₄)⁺.

Example 18D tert-butyl4-(4-(2-bromobenzyl)-4-methoxycyclohexyl)-1-piperazinecarboxylate

The desired product was prepared by substituting EXAMPLE 18C for EXAMPLE15C in EXAMPLE 15D. MS (ESI) m/e 468 (M+H)⁺.

Example 18E 1-(4-(2-bromobenzyl)-4-methoxycyclohexyl)piperazine

The desired product was prepared by substituting EXAMPLE 18D for EXAMPLE15D in EXAMPLE 15E. MS (ESI) m/e 367 (M+H)⁺.

Example 18F methyl4-(4-(2-bromobenzyl)-4-methoxycyclohexyl)-N-cyano-1-piperazinecarbimidothioate

The desired product was prepared by substituting EXAMPLE 18E for1-(4-benzyl-4-methoxycyclohexyl)piperazine in EXAMPLE 13A. MS

Example 18G4-(4-(2-bromobenzyl)-4-methoxycyclohexyl)-N-cyano-N′-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-1-piperazinecarboximidamide

The desired product was prepared by substituting EXAMPLE 18F for EXAMPLE13A in EXAMPLE 13B. MS

Example 18H4-(4-(2-bromobenzyl)-4-methoxycyclohexyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-1-piperazinecarboximidamide

The desired product was prepared by substituting EXAMPLE 18G for EXAMPLE13B in EXAMPLE 13C. MS; ¹H NMR (300 MHz, CD₃OD) δ 8.44 (d, 1H), 7.75 (m,1H), 7.53 (m, 1H), 7.29 (m, 4H), 7.16 (m, 3H), 7.09 (m, 1H), 6.97 (m,1H), 4.11 (m, 1H), 3.44 (m, 9H), 3.34 (d, 3H), 3.15 (m, 8H), 3.00 (d,2H), 2.60 (m, 2H), 2.31 (m, 2H), 1.91 (m, 1H), 1.69 (m, 3H), 1.42 (m,3H).

Example 194-(4-methoxy-4-(2-methylbenzyl)-1-piperidinyl)-N-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting2-phenylsulfanylethylamine (prepared according to the proceduredescribed in Chem. Pharm. Bull 1995, 43, 2091-2094) and EXAMPLE 8D forEXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N. MS (ESI) m/e 672(M−H)⁻; ¹H NMR (500 MHz, CDCl₃) δ 8.76 (d, 1H), 8.53 (t, 1H), 8.16 (brs, 1H), 7.93 (dd, 1H), 7.68 (d, 2H), 7.40 (d, 2H), 7.26 (m, 2H), 7.13(m, 4H), 6.88 (d, 2H), 6.77 (d, 1H), 3.55 (m, 4H), 3.36 (s, 3H), 3.16(m, 4H), 2.85 (s, 2H), 2.32 (s, 3H), 1.87 (d, 2H), 1.69 (m, 2H).

Example 20N-((4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-methoxy-4-(2-methylbenzyl)-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting1,1-dimethyl-2-phenylsulfanyl-ethylamine (prepared according to theprocedure described in commonly owned U.S. patent application Ser. No.09/957,256, filed Sep. 20, 2001) and EXAMPLE 8D for EXAMPLE 1M andEXAMPLE 1I, respectively, in EXAMPLE 1N. MS (ESI) m/e 702 (M+H)⁺; ¹H NMR(500 MHz, DMSO-d₆) δ 8.79 (s, 1H), 8.45 (s, 1H), 8.39 (d, 1H), 8.00 (s,1H), 7.79 (d, 2H), 7.75 (dd, 1H), 7.32 (d, 1H), 7.25 (d, 2H), 7.11 (m,4H), 7.00 (t, 2H), 6.93 (m, 3H), 3.64 (d, 2H), 3.52 (s, 2H), 3.28 (s,3H), 2.97 (m, 2H), 2.80 (s, 2H), 2.27 (s, 3H), 1.75 (d, 2H), 1.55 (s,6H), 1.50 (m, 2H).

Example 214-(4-methoxy-4-(2-methylbenzyl)-1-piperidinyl)-N-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide

Example 21A benzyl (3R)-2,5-dioxotetrahydro-3-furanylcarbamate

A stirred suspension of N-(benzyloxycarbonyl)-D-aspartic acid (14.7 g,55.1 mmol) in ethyl acetate (100 mL) was treated dropwise with thionylchloride (40 mL, 511 mmol) and the resulting homogeneous mixture wasstirred at room temperature for 16 hours, and concentrated. Theresulting solid was triturated in 1:1 diethyl ether/hexanes (200 mL) for2 hours and filtered. The solid was dried to provide the desired product(13.7 g, 99%).

Example 21B benzyl(3R)-5-oxotetrahydro-3-furanylcarbamate

A suspension of NaBH₄ (2.71 g, 71.5 mmol) in THF (50 mL) was cooled to0° C., treated dropwise with a solution of EXAMPLE 21A (16.21 g, 65.0mmol) in THF (50 mL), allowed to warm to room temperature, and stirredfor 2 hours. The resulting mixture was treated with concentrated HCl(13.1 mL) and ethanol (13.1 mL), heated to reflux for 12 hours, allowedto cool to room temperature, poured into brine (100 mL) and the layerswere separated. The aqueous phase was extracted with ethyl acetate andthe combined organic layers were washed with water and brine, dried(MgSO₄), filtered, and concentrated. The concentrate was triturated withdiethyl ether (50 mL) for 2 hours, cooled overnight, and the solidcollected by filtration to provide the desired product (7.81 g, 51%).

Example 21Cbenzyl(1R)-1-(hydroxymethyl)-3-(4-morpholinyl)-3-oxopropylcarbamate

A solution of EXAMPLE 21B (13.5 g, 57.4 mmol) and morpholine (10.0 mL,115 mmol) in dioxane (100 mL) was stirred at 70° C. for 18 hours. Thesolution was concentrated and purified by silica gel chromatographyeluting with 10% methanol/ethyl acetate to provide the desired product6.0 g, 86%).

Example 21Dbenzyl(1R)-3-(4-morpholinyl)-3-oxo-1-((phenylsulfanyl)methyl)propylcarbamate

A solution of EXAMPLE 21C (16.5 g, 51.2 mmol), diphenyldisulfide (14.5g, 66.5 mmol) and tributylphosphine (16.6 mL, 66.5 mmol) in toluene (250mL) was heated to 80° C. for 24 hours, concentrated, and purified bysilica gel chromatography eluting with 50% ethyl acetate/hexanes toprovide a mixture of the desired product containing approximately 10%tributylphosphine oxide (18.0 g mixture, ˜76%) that was carried onwithout further purification.

Example 21E(1R)-3-(4-morpholinyl)-3-oxo-1-((phenylsulfanyl)methyl)propylamine

A solution of EXAMPLE 21D (18.0 g, ˜39 mmol) in 30% HBr in acetic acid(250 mL) was stirred for 24 hours at room temperature, concentrated tohalf its volume, poured into 1M HCl (300 mL), washed with diethyl ether(3×200 mL), and extracted with 1M HCl (150 mL). The combined aqueouslayers were cooled to 0° C., adjusted to pH ˜12 with solid KOH, andextracted with dichloromethane (5×100 mL). The combined extracts werewashed with brine, dried (Na₂SO₄), filtered, and concentrated to providethe desired product (10.8 g, 98%).

Example 21F (1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propylamine

A solution of EXAMPLE 21E (6.00 g, 21.4 mmol) in THF (80 mL) was heatedto 55° C. and treated dropwise with a solution of 1M borane in THF (85mL, 85.0 mmol) over a 1 hour period. The resulting reaction mixture wasstirred at 55° C. for 18 hours, cooled to 0° C., treated dropwise withmethanol (10 mL), treated with 150 mL additional methanol, andconcentrated. The crude residue was dissolved in methanol (70 mL),treated with methanolic HCl (100 mL), and heated to reflux for 24 hours.The mixture was allowed to cool to room temperature, concentrated,diluted with 2M NaOH (200 mL), and extracted with ethyl acetate (3×250mL). The combined extracts were washed with 1M NaOH and brine, dried(Na₂SO₄), filtered, concentrated, and purified by silica gelchromatography eluting with 5% triethylamine/10% methanol/10%acetonitrile/ethyl acetate to provide the desired product (3.45 g, 73%).

Example 21G4-(4-methoxy-4-(2-methylbenzyl)-1-piperidinyl)-N-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 21F and EXAMPLE8D for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N. MS (ESI)m/e 785 (M−H)⁻; ¹H NMR (500 MHz, CDCl₃) δ 8.65 (d, 1H), 8.21 (d, 1H),8.12 (br, 1H), 7.83 (dd, 1H), 7.68 (d, 2H), 7.30 (m, 2H), 7.15 (m, 6H),6.85 (d, 2H), 6.67 (d, 1H), 6.37 (br, 1H), 4.01 (br, 2H), 3.95 (br, 4H),3.56 (d, 2H), 3.36 (s, 3H), 3.14 (m, 7H), 2.84 (s, 2H), 2.84 (br, 2H),2.40 (m, 1H), 2.32 (s, 3H), 2.17 (m, 1H), 1.86 (d, 2H), 1.65 (m, 2H).

Example 224-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)-1-piperazinyl)-N-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide

Example 22A tert-butyl 4-(2-bromobenzyl)-1-piperazinecarboxylate

A solution of tert-butyl 1-piperazinecarboxylate (5.51 g, 29.623 mmol)in acetonitrile (60 mL) at 0° C. was treated with diisopropylethylamineand 2-bromobenzyl bromide (7.776 g, 31.105 mmol), warmed to roomtemperature, stirred for 2 hours, and concentrated. The residue waspartitioned between ethyl acetate and aqueous NaHCO₃. The aqueous layerwas extracted with ethyl acetate and the combined extracts were dried(MgSO₄), filtered, and concentrated. The concentrate was used directlyin the next step without further purification.

Example 22B tert-butyl4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)-1-piperazinecarboxylate

A solution of EXAMPLE 22A (5.82 g, 16.394 mmol) in DME (80 mL) wastreated with 4-chlorophenylboronic acid (3.089 g, 19.673 mmol), CsF(7.476 g, 49.182 mmol) and (Ph₃P)₂Pd(OAc)₂ (1.228 g, 1.639 mmol), heatedto reflux for 4 hours, and filtered. The filtrate was partitionedbetween aqueous NaHCO₃ and ethyl acetate. The aqueous layer wasextracted with ethyl acetate and the combined extracts were dried(MgSO₄), filtered, and concentrated. The residue was purified by silicagel column chromatography with 15% ethyl acetate/hexane to provide thedesired product. MS (ESI) m/e 386, 388 (M+H)⁺.

Example 22C 1-((4′-chloro-1,1′-biphenyl-2-yl)methyl)piperazine

A solution of EXAMPLE 22B (1.00 g, 2.59 mmol) in dioxane (20 mL) at roomtemperature was treated with 4N HCl in dioxane (19.4 mL, 77.7 mmol),stirred overnight. Solvent was removed under reduced pressure. Theresidue was further dried under vacuum and used for the next stepwithout further purification.

Example 22D4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)-1-piperazinyl)benzonitrile

A solution of EXAMPLE 22C (932 mg, 2.591 mmol) in DMSO (13 mL) wastreated with 4-fluorobenzonitrile (408 mg, 3.368 mmol) and K₂CO₃ (1.788g, 12.955 mmol), heated at 130° C. for 4 hours, and filtered. Thefiltrate was partitioned between aqueous NaHCO₃ and ethyl acetate. Theaqueous layer was extracted with ethyl acetate. The combined extractswere dried (MgSO₄), filtered, and concentrated. The residue was purifiedby silica gel column chromatography with 20% ethyl acetate/hexanes toprovide the desired product. MS (ESI) m/e 388, 390 (M+H)⁺.

Example 22E4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)-1-piperazinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 22D for EXAMPLE12A in EXAMPLE 12B.

Example 22F4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)-1-piperazinyl)-N-((4-fluoro-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 22E for EXAMPLE1H in EXAMPLE 1I. MS (ESI) m/e 608, 610 (M+H)⁺.

Example 22G4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)-1-piperazinyl)-N-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 22F and2-phenylsulfanyl-ethylamine for EXAMPLE 1I and EXAMPLE 1M, respectively,in EXAMPLE 1N. MS (APCI) m/e 741, 743 (M+H); ¹H NMR (300 MHz, CDCl₃) δ8.76 (d, 1H), 8.56 (t, 1H), 8.22 (br, 1H), 7.93 (dd, 1H), 7.77 (m, 1H),7.68 (d, 2H), 7.45 (m, 4H), 7.26 (m, 7H), 6.77 (dd, 3H), 6.16 (br, 1H),4.31 (s, 2H), 3.56 (q, 2H), 3.47 (br, 4H), 3.19 (t, 2H), 1.65 (br, 4H).

Example 234-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)-1-piperazinyl)-N-((4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 22F and1,1-dimethyl-2-phenylsulfanylethylamine for EXAMPLE 1I and EXAMPLE 1M,respectively, in EXAMPLE 1N. MS (APCI) m/e 769, 771 (M+H); ¹H NMR (300MHz, CDCl₃) δ 8.84 (s, 1H), 8.46 (s, 1H), 8.39 (d, 1H), 8.04 (s, 1H),7.81 (d, 2H), 7.75 (dd, 1H), 7.50 (m, 4H), 7.36 (m, 3H), 7.25 (m, 3H),6.97 (m, 5H), 3.52 (s, 2H), 3.33 (m, 6H), 2.39 (m, 4H), 1.55 (s, 6H).

Example 244-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)-1-piperazinyl)-N-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 22F and EXAMPLE21D for EXAMPLE 1I and EXAMPLE 1M, respectively, in EXAMPLE 1N. MS (ESI)m/e 852, 854 (M−H); ¹H NMR (300 MHz, CDCl₃) δ 8.72 (d, 1H), 8.50 (d,1H), 8.21 (br, 1H), 7.82 (dd, 1H), 7.69 (d, 2H), 7.49 (m, 1H), 7.28 (m,11H), 6.81 (d, 2H), 6.71 (d, 1H), 6.08 (br, 1H), 4.00 (br, 1H), 3.67 (s,4H), 3.41 (s, 2H), 3.26 (t, 4H), 3.12 (t, 2H), 2.43 (m, 10H), 2.14 (m,1H), 1.77 (m, 1H).

Example 254-(4-(1,1′-biphenyl-2-ylmethyl)-4-methoxy-1-piperidinyl)-N-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide

Example 25A 4-(4-(2-bromobenzyl)-4-hydroxy-1-piperidinyl)benzonitrile

The desired product was prepared by substituting 2-bromobenzylmagnesiumbromide for benzylmagnesium chloride in EXAMPLE 5A. MS (ESI) m/e 371,373 (M+H)⁺.

Example 25B 4-(4-(2-bromobenzyl)-4-methoxy-1-piperidinyl)benzonitrile

The desired product was prepared by substituting EXAMPLE 25A for EXAMPLE1C in EXAMPLE 1D. MS (ESI) m/e 385, 387 (M+H)⁺.

Example 25C4-(4-(1,1′-biphenyl-2-ylmethyl)-4-methoxy-1-piperidinyl)benzonitrile

The desired product was prepared by substituting EXAMPLE 25B andphenylboronic acid for EXAMPLE 22A and 4-chlorophenylboronic acid,respectively, in EXAMPLE 22B. MS (ESI) m/e 383 (M+H)⁺.

Example 25D4-(4-(1,1′-biphenyl-2-ylmethyl)-4-methoxy-1-piperidinyl)benzenecarboximidamide

The desired product was obtained by substituting EXAMPLE 25C for EXAMPLE12A in EXAMPLE 12B.

Example 25E4-(4-(1,1′-biphenyl-2-ylmethyl)-4-methoxy-1-piperidinyl)-N-((4-fluoro-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was obtained by substituting EXAMPLE 25D for EXAMPLE1H in EXAMPLE 1I. MS (ESI) m/e 603 (M+H)⁺.

Example 25F4-(4-(1,1′-biphenyl-2-ylmethyl)-4-methoxy-1-piperidinyl)-N-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 25E and2-phenylsulfanyl-ethylamine for EXAMPLE 1I and EXAMPLE 1M, respectivelyin EXAMPLE 1N. MS (ESI) m/e 731 (M−H); ¹H NMR (500 MHz, CDCl₃) δ 8.75(d, 1H), 8.53 (t, 1H), 8.15 (br, 1H), 7.93 (dd, 1H), 7.65 (d, 2H), 7.40(m, 3H), 7.27 (m, 10H), 6.81 (d, 2H), 6.77 (d, 1H), 6.21 (br, 1H), 3.55(q, 2H), 3.35 (d, 2H), 3.18 (t, 2H), 3.12 (s, 3H), 2.99 (m, 2H), 2.94(s, 2H), 1.59 (d, 2H), 1.40 (m, 2H).

Example 264-(4-(1,1′-biphenyl-2-ylmethyl)-4-methoxy-1-piperidinyl)-N-((4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 25E and1,1-dimethyl-2-phenylsulfanylethylamine for EXAMPLE 1I and EXAMPLE 1M,respectively in EXAMPLE 1N. MS (ESI) m/e 762 (M−H)⁻; ¹H NMR (500 MHz,CDCl₃) δ 8.65 (d, 1H), 8.18 (br, 1H), 7.81 (dd, 1H), 7.67 (d, 2H), 7.37(m, 3H), 7.27 (m, 8H), 7.03 (m, 3H), 6.94 (d, 1H), 6.78 (d, 2H), 6.14(br, 1H), 3.35 (br, 4H), 3.12 (s, 3H), 2.97 (t, 2H), 2.94 (s, 2H), 1.59(s, 6H), 1.57 (br, 2H), 1.36 (br, 2H).

Example 274-(4-(1,1′-biphenyl-2-ylmethyl)-4-methoxy-1-piperidinyl)-N-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 25E and EXAMPLE21D for EXAMPLE 1I and EXAMPLE 1M, respectively in EXAMPLE 1N. MS (ESI)m/e 847 (M−H)⁻; ¹H NMR (500 MHz, CDCl₃) δ 8.64 (d, 1H), 8.21 (d, 1H),8.12 (br, 1H), 7.83 (dd, 1H), 7.67 (d, 2H), 7.39 (t, 2H), 7.29 (m, 8H),7.20 (m, 3H), 6.85 (d, 2H), 6.67 (d, 1H), 6.38 (br, 1H), 3.99 (br, 6H),3.35 (d, 2H), 3.15 (m, 8H), 3.02 (m, 2H), 2.94 (s, 2H), 2.82 (br, 2H),2.40 (m, 1H), 2.18 (m, 1H), 1.60 (d, 2H), 1.41 (m, 2H).

Example 284-(4-(1,1′-biphenyl-2-ylmethylene)-1-piperidinyl)-N′-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide

Example 28A4-(4-(1,1′-biphenyl-2-ylmethylene)-1-piperidinyl)benzonitrile

The desired product was prepared by substituting biphenyl-2-ylmethyltriphenyl-phosphonium bromide (prepared according to the proceduredescribed in J. Org. Chem. 2000, 65, 543-577) for 4-fluorobenzyltriphenylphosphonium chloride in EXAMPLE 9A. MS (ESI) m/e 351 (M+H)⁺.

Example 28B4-(4-(1,1′-biphenyl-2-ylmethylene)-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 28A for EXAMPLE12A in EXAMPLE 12B. MS (DCI) m/e 368 (M+H)⁺.

Example 28C4-(4-(1,1′-biphenyl-2-ylmethylene)-1-piperidinyl)-N′-((4-fluoro-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 28B for EXAMPLE1H in EXAMPLE 1I. MS (ESI) m/e 571 (M+H)⁺.

Example 28D4-(4-(1,1′-biphenyl-2-ylmethylene)-1-piperidinyl)-N′-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 28C and2-phenylsulfanyl-ethylamine for EXAMPLE 1I and EXAMPLE 1M, respectively,in EXAMPLE 1N. MS (ESI) m/e 702 (M−H); ¹H NMR (400 MHz, DMSO-d₆) δ 8.78(s, 1H), 8.64 (t, 1H), 8.48 (d, 1H), 7.98 (s, 1H), 7.85 (dd, 1H), 7.77(d, 2H), 7.33 (m, 11H), 7.28 (m, 2H), 7.15 (m, 2H), 6.92 (d, 2H), 6.17(s, 1H), 3.63 (m, 2H), 3.40 (t, 2H), 3.26 (t, 2H), 3.21 (t, 2H), 2.25(t, 4H).

Example 294-(4-(1,1′-biphenyl-2-ylmethylene)-1-piperidinyl)-N′-((4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 28C and1,1-dimethyl-2-phenylsulfanylethylamine for EXAMPLE 1I and EXAMPLE 1M,respectively, in EXAMPLE 1N. MS (ESI) m/e 73) (M−H)⁻; ¹H NMR (400 MHz,DMSO-d₆) δ 8.80 (s, 1H), 8.65 (s, 1H), 8.39 (d, 1H), 8.02 (s, 1H), 7.81(d, 2H), 7.75 (dd, 1H), 7.35 (m, 10H), 7.24 (m, 3H), 7.01 (m, 2H), 6.94(d, 2H), 6.16 (s, 1H), 3.52 (s, 2H), 3.40 (t, 2H), 3.22 (t, 2H), 2.26(t, 4H), 1.55 (s, 6H).

Example 304-(4-(1,1′-biphenyl-2-ylmethylene)-1-piperidinyl)-N′-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 28C and EXAMPLE21D for EXAMPLE 1I and EXAMPLE 1M, respectively, in EXAMPLE 1N. MS (ESI)m/e 815 (M−H)⁻; ¹H NMR (400 MHz, DMSO-d₆) δ 8.77 (s, 1H), 8.43 (d, 1H),8.38 (d, 1H), 7.98 (s, 1H), 7.77 (m, 3H), 7.33 (m, 11H), 7.13 (m, 4H),6.93 (d, 2H), 6.16 (s, 1H), 4.15 (m, 1H), 3.48 (m, 4H), 3.40 (t, 2H),3.35 (t, 2H), 3.28 (t, 2H), 3.21 (t, 2H), 2.28 (m, 6H), 2.18 (m, 2H),1.98 (m, 1H), 1.90 (m, 1H).

Example 31N′-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)-4-(4-(2-(trifluoromethyl)benzylidene)-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 10C and2-phenylsulfanyl-ethylamine for EXAMPLE 1I and EXAMPLE 1M, respectively,in EXAMPLE 1N. MS (ESI) m/e 693 (M−H)⁻; ¹H NMR (400 MHz, DMSO-d₆) δ 8.80(s, 1H), 8.65 (t, 1H), 8.48 (d, 1H), 8.01 (s, 1H), 7.85 (dd, 1H), 7.79(d, 2H), 7.72 (d, 1H), 7.63 (m, 1H), 7.47 (m, 1H), 7.35 (m, 3H), 7.26(m, 2H), 7.15 (m, 2H), 6.97 (d, 2H), 6.50 (s, 1H), 3.64 (m, 2H), 3.51(t, 2H), 3.38 (t, 2H), 3.26 (t, 2H), 2.42 (t, 2H), 2.24 (t, 2H).

Example 32N′-((4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-(trifluoromethyl)benzylidene)-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 10C and1,1-dimethyl-2-phenylsulfanylethylamine for EXAMPLE 1I and EXAMPLE 1M,respectively, in EXAMPLE 1N. MS (ESI) m/e 722 (M−H)⁻; ¹H NMR (400 MHz,DMSO-d₆) δ 8.83 (s, 1H), 8.46 (s, 1H), 8.39 (d, 1H), 8.04 (s, 1H), 7.84(d, 2H), 7.75 (m, 2H), 7.63 (m, 1H), 7.46 (m, 1H), 7.34 (m, 2H), 7.23(d, 2H), 6.97 (m, 5H), 6.50 (s, 1H), 3.52 (m, 4H), 3.38 (t, 2H), 2.43(t, 2H), 2.25 (t, 4H), 1.55 (s, 6H).

Example 33N′-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-(trifluoromethyl)benzylidene)-1-piperidinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 10C and EXAMPLE21D for EXAMPLE 1I and EXAMPLE 1M, respectively, in EXAMPLE 1N. MS (ESI)m/e 806 (M−H)⁻; ¹H NMR (400 MHz, DMSO-d₆) δ 8.79 (s, 1H), 8.43 (d, 1H),8.38 (d, 1H), 8.00 (s, 1H), 7.77 (m, 4H), 7.63 (m, 1H), 7.47 (m, 1H),7.36 (m, 1H), 7.27 (m, 2H), 7.13 (m, 4H), 6.97 (d, 2H), 6.49 (s, 1H),4.15 (m, 1H), 3.49 (m, 6H), 3.38 (m, 4H), 2.42 (t, 2H), 2.25 (m, 8H),1.96 (m, 1H), 1.89 (m, 1H).

Example 344-(4-(3,3-diphenyl-2-propenyl)-1-piperazinyl)-N′-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide

Example 34A4-(4-(3,3-diphenyl-2-propenyl)-1-piperazinyl)-N′-((4-fluoro-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired compound was prepared by substituting EXAMPLE 12B forEXAMPLE 1H in EXAMPLE 1I. MS (ESI) m/e 600 (M+H).

Example 34B4-(4-(3,3-diphenyl-2-propenyl)-1-piperazinyl)-N′-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 34A and2-phenylsulfanyl-ethylamine for EXAMPLE 1I and EXAMPLE 1M, respectively,in EXAMPLE 1N. MS (ESI) m/e 731 (M−H)⁻; ¹H NMR (400 MHz, DMSO-d₆) δ 8.78(s, 1H), 8.64 (t, 1H), 8.48 (d, 1H), 8.01 (s, 1H), 7.85 (dd, 1H), 7.75(d, 2H), 7.40-7.10 (m, 16H), 6.97 (d, 2H), 6.18 (t, 1H), 3.64 (m, 2H),3.27 (m, 6H), 3.01 (d, 2H), 2.44 (t, 4H).

Example 35N′-((4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(3,3-diphenyl-2-propenyl)-1-piperazinyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 34A and1,1-dimethyl-2-phenylsulfanylethylamine for EXAMPLE 1I and EXAMPLE 1M,respectively, in EXAMPLE 1N. MS (ESI) m/e 759 (M−H); ¹H NMR (400 MHz,DMSO-d₆) δ 8.83 (s, 1H), 8.45 (s, 1H), 8.39 (d, 1H), 8.04 (s, 1H), 7.81(d, 2H), 7.75 (dd, 1H), 7.43-7.20 (m, 12H), 7.13 (d, 2H), 6.97 (m, 4H),6.19 (t, 1H), 3.51 (s, 2H), 3.30 (m, 4H), 3.01 (d, 2H), 2.45 (t, 4H),1.55 (s, 6H).

Example 364-(4-(3,3-diphenyl-2-propenyl)-1-piperazinyl)-N′-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide

The desired product was prepared by substituting EXAMPLE 34A and EXAMPLE21D for EXAMPLE 1I and EXAMPLE 1M, respectively, in EXAMPLE 1N. MS (ESI)m/e 844 (M−H)⁻; ¹H NMR (400 MHz, DMSO-d₆) δ 8.79 (s, 1H), 8.43 (d, 1H),8.38 (d, 1H), 8.00 (s, 1H), 7.77 (m, 3H), 7.45-7.10 (m, 16H), 6.92 (d,2H), 6.19 (t, 1H), 4.15 (m, 1H), 3.47 (m, 4H), 3.38 (m, 2H), 3.29 (m,4H), 3.01 (d, 2H), 2.45 (m, 4H), 2.31 (m, 4H), 2.18 (m, 2H), 1.96 (m,1H), 1.81 (m, 1H).

Following the procedures described in the EXAMPLEs and the schemes, thefollowing compounds may be prepared:

wherein R² is one of the following structures:

is one of the following structures:

andR⁴ is one of the following structures:

1. A compound of formula (I)

or a therapeutically acceptable salt thereof, wherein A is a five-,six-, or seven-membered aromatic or non-aromatic ring wherein from zeroto three carbon atoms are replaced by a heteroatom selected from thegroup consisting of nitrogen, oxygen, and sulfur; R¹ is selected fromthe group consisting of alkyl, cyano, halo, haloalkyl, nitro, and—NR⁵R⁶; R², and R³ are independently selected from the group consistingof hydrogen, alkenyl, alkoxy, alkyl, alkylcarbonyloxy, alkylsulfanyl,alkynyl, aryl, arylalkoxy, aryloxy, aryloxyalkoxy, arylsulfanyl,arylsulfanylalkoxy, cycloalkylalkoxy, cycloalkyloxy, halo, haloalkoxy,haloalkyl, heterocyclyl, heterocyclyloxy, hydroxy, nitro, and —NR⁵R⁶; R⁴is selected from the group consisting of aryl, arylalkenyl, arylalkoxy,cycloalkenyl, cycloalkyl, heterocyclyl, and heterocyclylalkoxy; R⁵ andR⁶ are independently selected from the group consisting of hydrogen,alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, alkylsulfanylalkyl,alkylsulfonylalkyl, aryl, arylalkyl, arylalkylsulfanylalkyl,aryloxyalkyl, arylsulfanylalkyl, arylsulfinylalkyl, arylsulfonylalkyl,carboxyalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkyl,(cycloalkyl)alkyl, cycloalkylcarbonyl, heterocyclyl, heterocyclylalkyl,heterocyclylsulfanylalkyl, hydroxyalkyl, and a nitrogen protectinggroup; or R⁵ and R⁶, together with the nitrogen atom to which they areattached, form a ring selected from the group consisting of imidazolyl,morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, pyrrolyl,thiomorpholinyl, and thiomorpholinyl dioxide; and R¹⁵ is selected fromthe group consisting of hydrogen, alkoxy, alkyl, and halo.
 2. Thecompound of claim 1 wherein R³ and R¹⁵ are hydrogen.
 3. The compound ofclaim 2 wherein R² is —NR⁵R⁶.
 4. The compound of claim 3 wherein one ofR⁵ and R⁶ is hydrogen and the other is arylsulfanylalkyl.
 5. Thecompound of claim 4 wherein A is piperazinyl.
 6. The compound of claim 5selected from the group consisting of4-(4-benzyl-4-methoxycyclohexyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-1-piperazinecarboximidamide;N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-phenyl-1-piperazinecarboximidamide;N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-methoxy-4-(2-methylbenzyl)cyclohexyl)-1-piperazinecarboximidamide;4-(4-(2-chlorobenzyl)-4-methoxycyclohexyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-1-piperazinecarboximidamide;N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-fluorobenzyl)-4-methoxycyclohexyl)-1-piperazinecarboximidamide;and4-(4-(2-bromobenzyl)-4-methoxycyclohexyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-1-piperazinecarboximidamide.7. The compound of claim 4 wherein A is phenyl.
 8. The compound of claim7 wherein R⁴ is piperidinyl.
 9. The compound of claim 8 selected fromthe group consisting ofN-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-fluorobenzyl)-4-methoxy-1-piperidinyl)benzenecarboximidamide;N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4,4-dimethyl-1-piperidinyl)benzenecarboximidamide;N-((4-(((1R)-5-(dimethylamino)-1-((phenylsulfanyl)methyl)pentyl)amino)-3-nitrophenyl)sulfonyl)-4-(4,4-dimethyl-1-piperidinyl)benzenecarboximidamide;4-(4,4-dimethyl-1-piperidinyl)-N-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide;4-(4-benzyl-4-methoxy-1-piperidinyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;4-(4-(cyclohexylmethyl)-4-methoxy-1-piperidinyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;4-(4-(2,4-difluorobenzyl)-4-methoxy-1-piperidinyl)-N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-methoxy-4-(2-methylbenzyl)-1-piperidinyl)benzenecarboximidamide;N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(4-fluorobenzylidene)-1-piperidinyl)benzenecarboximidamide;N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-(trifluoromethyl)benzylidene)-1-piperidinyl)benzenecarboximidamide;N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(3-thienylmethylene)-1-piperidinyl)benzenecarboximidamide;4-(4-methoxy-4-(2-methylbenzyl)-1-piperidinyl)-N-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide;N-((4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-methoxy-4-(2-methylbenzyl)-1-piperidinyl)benzenecarboximidamide;4-(4-methoxy-4-(2-methylbenzyl)-1-piperidinyl)-N-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;4-(4-(1,1′-biphenyl-2-ylmethyl)-4-methoxy-1-piperidinyl)-N-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide;4-(4-(1,1′-biphenyl-2-ylmethyl)-4-methoxy-1-piperidinyl)-N-((4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;4-(4-(1,1′-biphenyl-2-ylmethyl)-4-methoxy-1-piperidinyl)-N-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;4-(4-(1,1′-biphenyl-2-ylmethylene)-1-piperidinyl)-N′-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide;4-(4-(1,1′-biphenyl-2-ylmethylene)-1-piperidinyl)-N′-((4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;4-(4-(1,1′-biphenyl-2-ylmethylene)-1-piperidinyl)-N′-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;N′-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)-4-(4-(2-(trifluoromethyl)benzylidene)-1-piperidinyl)benzenecarboximidamide;N′-((4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-(trifluoromethyl)benzylidene)-1-piperidinyl)benzenecarboximidamide;andN′-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-(trifluoromethyl)benzylidene)-1-piperidinyl)benzenecarboximidamide.10. The compound of claim 7 wherein R⁴ is piperazinyl.
 11. The compoundof claim 10 selected from the group consisting ofN-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(3,3-diphenyl-2-propenyl)-1-piperazinyl)benzenecarboximidamide;4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)-1-piperazinyl)-N-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide;4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)-1-piperazinyl)-N-((4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;4-(4-((4′-chloro-1,1′-biphenyl-2-yl)methyl)-1-piperazinyl)-N-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide;4-(4-(3,3-diphenyl-2-propenyl)-1-piperazinyl)-N′-((3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)phenyl)sulfonyl)benzenecarboximidamide;N′-((4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(3,3-diphenyl-2-propenyl)-1-piperazinyl)benzenecarboximidamide;and4-(4-(3,3-diphenyl-2-propenyl)-1-piperazinyl)-N′-((4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzenecarboximidamide.12. A pharmaceutical composition comprising a compound of claim 1 or atherapeutically acceptable salt thereof, in combination with atherapeutically acceptable carrier.
 13. A method of promoting apoptosisin a mammal in recognized need of such treatment comprisingadministering to the mammal a therapeutically acceptable amount of acompound of claim 1, or a therapeutically acceptable salt thereof.